{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "accomplished-question",
   "metadata": {
    "kernel": "SoS"
   },
   "source": [
    "# Extracting the overall response rate (ORR) "
   ]
  },
  {
   "cell_type": "markdown",
   "id": "sonic-disney",
   "metadata": {
    "kernel": "SoS"
   },
   "source": [
    "This is an advanced notebook. If you are new to IRuta Notebooks, then please start with the Notebook: `Notebook [IRuta] - Get started.ipynb`"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "nearby-fellow",
   "metadata": {
    "kernel": "SoS"
   },
   "source": [
    "This notebook will show you how **batch processing** works. In batch processing, Ruta rules are applied to a collection of documents. In this example IRuta Notebook, the documents are 100 PubMed abstracts. The goal is to extract the overall response rate (ORR). ORR is defined as the proportion of patients who have a partial or complete response to therapy. The results should be collected in a CSV-Table."
   ]
  },
  {
   "cell_type": "markdown",
   "id": "integral-financing",
   "metadata": {
    "kernel": "SoS"
   },
   "source": [
    "## Step 1: Extracting sentences, ORR-indicators and numbers\n",
    "We are reading the files from an input directory. This means that all text files from that directory are processed. For each file, the script:\n",
    "1. Extracts sentences\n",
    "2. Annotates mentionings of the overall response rate (plus synonyms) and find numeric values\n",
    "3. Collect sentences with overall response rate indicator in a Table\n",
    "\n",
    "We write the intermediate results into a new directory by setting the output directory."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "instrumental-watson",
   "metadata": {
    "kernel": "UIMA Ruta"
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Processed 100/100 files. (took 2s)\n",
      "205 rows created.\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<html><table>\n",
       "<tr><td>21723792.txt</td><td>ineligible. The primary endpoint was<br />investigator-assessed <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span>; secondary endpoints were PFS, <br />overall survival (OS), safety, and quality of life.<br />RESULTS</td></tr>\n",
       "<tr><td>21723792.txt</td><td>). The <span style='background:#90ee90'>ORR</span>s were <span style='background:#ffc0cb'>48</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>9</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> confidence<br />interval [CI], <span style='background:#ffc0cb'>38</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>5</span><span style='background:#ffc0cb'>%</span><span style='background:#ffc0cb'>-</span><span style='background:#ffc0cb'>59</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>5</span><span style='background:#ffc0cb'>%</span>) and <span style='background:#ffc0cb'>58</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>7</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI, <span style='background:#ffc0cb'>47</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>9</span><span style='background:#ffc0cb'>%</span><span style='background:#ffc0cb'>-</span><span style='background:#ffc0cb'>68</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>9</span><span style='background:#ffc0cb'>%</span>; P = .117</td></tr>\n",
       "<tr><td>21723792.txt</td><td>G.<br />CONCLUSION: The addition of gemcitabine to PB was not associated with a<br />statistically significant improvement in <span style='background:#90ee90'>ORR</span>. Treatment</td></tr>\n",
       "<tr><td>21399997.txt</td><td>2010. The primary endpoint was<br /><span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span>, and secondary endpoints were overall survival (OS)<br />and progression-free survival (PFS). Of</td></tr>\n",
       "<tr><td>21399997.txt</td><td>). Of the 40 evaluable female patients, the <span style='background:#90ee90'>ORR</span><br />was <span style='background:#ffc0cb'>62</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>5</span><span style='background:#ffc0cb'>%</span>. All</td></tr>\n",
       "<tr><td>22044606.txt</td><td>PSOC. The primary objective of this<br />subsequent phase II study was to determine the <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span> (<span style='background:#90ee90'>ORR</span>;<br />defined by Response Evaluation Criteria in Solid Tumors) of this combination in<br />patients with recurrent PSOC. Secondary</td></tr>\n",
       "<tr><td>22044606.txt</td><td>treated. Of the 61 patients evaluable for<br />response, there were 20 responders (one complete response and 19 partial<br />responses), for an <span style='background:#90ee90'>ORR</span> of <span style='background:#ffc0cb'>32</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>8</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI: <span style='background:#ffc0cb'>21</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>%</span>, <span style='background:#ffc0cb'>46</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>0</span><span style='background:#ffc0cb'>%</span>). For</td></tr>\n",
       "<tr><td>18981463.txt</td><td>periods. End points included<br />progression-free survival (PFS), objective response rate (<span style='background:#90ee90'>ORR</span>), overall survival <br />(OS), and safety.<br />RESULTS</td></tr>\n",
       "<tr><td>18815728.txt</td><td>weeks. The primary endpoint was <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span>.<br />Between</td></tr>\n",
       "<tr><td>18815728.txt</td><td>8. By intent-to-treat<br />analysis, <span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>21</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>1</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI, 8.7-43.7) and disease control rate was <span style='background:#ffc0cb'>52</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>6</span><span style='background:#ffc0cb'>%</span><br />(<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI 31.5-72.8) with four PRs and six SDs. Median</td></tr>\n",
       "<tr><td>16360546.txt</td><td>s. Clinical trials have shown that anthracycline-taxane combinations are more<br />effective than anthracyclines or taxanes alone in terms of overall response rates<br />(<span style='background:#90ee90'>ORR</span>), PFS and OS in women who have not received prior anthracycline<br />chemotherapy. The</td></tr>\n",
       "<tr><td>16360546.txt</td><td>patients. Carboplatin<br />combined with paclitaxel or docetaxel is more effective than carboplatin or<br />taxanes alone, with <span style='background:#90ee90'>ORR</span> of <span style='background:#ffc0cb'>53</span><span style='background:#ffc0cb'>-</span><span style='background:#ffc0cb'>62</span><span style='background:#ffc0cb'>%</span>. Taxane</td></tr>\n",
       "<tr><td>20819239.txt</td><td>agents.<br />METHODS: Data from 114 consecutive patients who had access to targeted agent were<br />analyzed for response rates (<span style='background:#90ee90'>ORR</span>), progression free survival (PFS) and overall<br />survival (OS). All</td></tr>\n",
       "<tr><td>20430469.txt</td><td>toxicity. The primary endpoint was<br />objective response rate (<span style='background:#90ee90'>ORR</span>). Secondary</td></tr>\n",
       "<tr><td>20430469.txt</td><td>21. <br />The <span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>53</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI, 38.6-67.9) and disease control rate (DCR) including<br />stable disease was <span style='background:#ffc0cb'>86</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>7</span><span style='background:#ffc0cb'>%</span>. The</td></tr>\n",
       "<tr><td>20430469.txt</td><td>out. The <span style='background:#90ee90'>ORR</span> and DCR were higher in patients with exon 19 deletions than those<br />with L858R (<span style='background:#ffc0cb'>62</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>1</span><span style='background:#ffc0cb'>%</span> vs <span style='background:#ffc0cb'>33</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>%</span>; P=0.0705 and <span style='background:#ffc0cb'>96</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>6</span><span style='background:#ffc0cb'>%</span> vs <span style='background:#ffc0cb'>66</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>7</span><span style='background:#ffc0cb'>%</span>; P=0.0062, respectively).<br />All</td></tr>\n",
       "<tr><td>21479652.txt</td><td>encouraging. In CLL, an <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> of<br /><span style='background:#ffc0cb'>65</span><span style='background:#ffc0cb'>%</span> was achieved. Notably</td></tr>\n",
       "<tr><td>21479652.txt</td><td>achieved. Notably, in the seven previously untreated CLL patients, <span style='background:#90ee90'>ORR</span><br />was <span style='background:#ffc0cb'>86</span><span style='background:#ffc0cb'>%</span>. The</td></tr>\n",
       "<tr><td>21479652.txt</td><td>). In indolent lymphoma (n = 25), the bendamustine-rituximab<br />combination induced a remarkable therapeutic effect (<span style='background:#90ee90'>ORR</span> <span style='background:#ffc0cb'>96</span><span style='background:#ffc0cb'>%</span>, median PFS and OS<br />not reached). In</td></tr>\n",
       "<tr><td>21479652.txt</td><td>). In aggressive lymphoma (n = 20), <span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>50</span><span style='background:#ffc0cb'>%</span>; in International<br />Prognostic Index high-risk patients (4 or 5 risk factors, n = 10), <span style='background:#90ee90'>ORR</span> was only<br /><span style='background:#ffc0cb'>20</span><span style='background:#ffc0cb'>%</span>, significantly inferior than in low/intermediate risk patients (<span style='background:#90ee90'>ORR</span> <span style='background:#ffc0cb'>70</span><span style='background:#ffc0cb'>%</span>; p = <br />0.025).<br />CONCLUSIONS</td></tr>\n",
       "<tr><td>21188632.txt</td><td>). Based on 35<br />evaluable patients, the <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> was <span style='background:#ffc0cb'>26</span><span style='background:#ffc0cb'>%</span> (1 CR and 8 PR), and <br />the clinical benefit rate (CR+ PR+ stable disease [SD] = 6 months) was <span style='background:#ffc0cb'>40</span><span style='background:#ffc0cb'>%</span>.<br />Median</td></tr>\n",
       "<tr><td>20371445.txt</td><td>granulocytopenia.<br />RESULTS: Overall response rate (<span style='background:#90ee90'>ORR</span>) and complete response (CR) were similar<br />among ESHAP and R-ESHAP (<span style='background:#90ee90'>ORR</span>, 33 patients [<span style='background:#ffc0cb'>62</span><span style='background:#ffc0cb'>%</span>] and 28 patients [<span style='background:#ffc0cb'>60</span><span style='background:#ffc0cb'>%</span>],<br />respectively; CR, 20 patients [<span style='background:#ffc0cb'>37</span><span style='background:#ffc0cb'>%</span>] and 18 patients [<span style='background:#ffc0cb'>36</span><span style='background:#ffc0cb'>%</span>], respectively).<br />Actuarial</td></tr>\n",
       "<tr><td>19826424.txt</td><td>day. The<br />primary end point was objective response rate (<span style='background:#90ee90'>ORR</span>). Secondary</td></tr>\n",
       "<tr><td>19826424.txt</td><td>safety.<br />RESULTS: Of 47 patients receiving sunitinib, one patient achieved a confirmed<br />partial response (<span style='background:#90ee90'>ORR</span> <span style='background:#ffc0cb'>2</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>1</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> confidence interval (CI) 0.1, 11.3)) and 11<br />(<span style='background:#ffc0cb'>23</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>4</span><span style='background:#ffc0cb'>%</span>) had stable disease (SD) > or =8 weeks. Five</td></tr>\n",
       "<tr><td>19853960.txt</td><td>weeks. Overall response rate<br />(<span style='background:#90ee90'>ORR</span>), progression-free survival (PFS), and overall survival (OS) were evaluated.<br />RESULTS</td></tr>\n",
       "<tr><td>19853960.txt</td><td>observed. The <span style='background:#90ee90'>ORR</span>s were <span style='background:#ffc0cb'>13</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>5</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI, 4.<span style='background:#ffc0cb'>5</span><span style='background:#ffc0cb'>-</span><span style='background:#ffc0cb'>28</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>8</span><span style='background:#ffc0cb'>%</span>) in <br />NSCLC and <span style='background:#ffc0cb'>44</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>8</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI, 26.<span style='background:#ffc0cb'>4</span><span style='background:#ffc0cb'>-</span><span style='background:#ffc0cb'>64</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>%</span>) in SCLC. In</td></tr>\n",
       "<tr><td>19853960.txt</td><td>SCLC. In SCLC, <span style='background:#90ee90'>ORR</span>s were <span style='background:#ffc0cb'>60</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>0</span><span style='background:#ffc0cb'>%</span> in the<br />sensitive relapse and <span style='background:#ffc0cb'>36</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>8</span><span style='background:#ffc0cb'>%</span> in the refractory relapse (p=0.2332). In</td></tr>\n",
       "<tr><td>21709202.txt</td><td>placebo. Primary end point was overall survival (OS);<br />secondary end points included <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> and progression-free<br />survival (PFS).<br />RESULTS</td></tr>\n",
       "<tr><td>21709202.txt</td><td>= .727), while <span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>25</span><span style='background:#ffc0cb'>%</span> in both arms (P =<br />1.0). Overall</td></tr>\n",
       "<tr><td>21561763.txt</td><td>toxicity. The primary<br />end-point was objective response rate (<span style='background:#90ee90'>ORR</span>). Secondary</td></tr>\n",
       "<tr><td>21561763.txt</td><td>). In<br />the intention to treat population (n=51); the <span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>9</span><span style='background:#ffc0cb'>%</span>, median PFS was 1.28<br />months [<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI, 1.18-1.90], median OS was 5.81 months [<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI, 3.48-12.32], the<br />estimated one-year survival rate was <span style='background:#ffc0cb'>23</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>7</span><span style='background:#ffc0cb'>%</span> [<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span>CI: 12.8-36.5]. In</td></tr>\n",
       "<tr><td>20521355.txt</td><td>SCLC.<br />METHODS: This trial aimed to achieve a <span style='background:#ffc0cb'>20</span><span style='background:#ffc0cb'>%</span> objective response rate (<span style='background:#90ee90'>ORR</span>) in<br />platinum-sensitive patients. Patients</td></tr>\n",
       "<tr><td>20521355.txt</td><td><span style='background:#ffc0cb'>%</span>. The overall <span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>19</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>6</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> confidence interval<br />[CI] <span style='background:#ffc0cb'>10</span><span style='background:#ffc0cb'>-</span><span style='background:#ffc0cb'>33</span><span style='background:#ffc0cb'>%</span>). Twelve</td></tr>\n",
       "<tr><td>20521355.txt</td><td>disease. Among relapse-sensitive patients, <span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>22</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>2</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI<br /><span style='background:#ffc0cb'>9</span><span style='background:#ffc0cb'>-</span><span style='background:#ffc0cb'>42</span><span style='background:#ffc0cb'>%</span>). Among</td></tr>\n",
       "<tr><td>20521355.txt</td><td>). Among relapse-refractory patients, <span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>16</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>7</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI <span style='background:#ffc0cb'>5</span><span style='background:#ffc0cb'>-</span><span style='background:#ffc0cb'>37</span><span style='background:#ffc0cb'>%</span>). Median</td></tr>\n",
       "<tr><td>21128114.txt</td><td>treatment. Analysis included overall survival (OS),<br />progression-free survival (PFS), objective response rate (<span style='background:#90ee90'>ORR</span>), and safety. In</td></tr>\n",
       "<tr><td>21128114.txt</td><td>vs. 3.1 months; HR, 0.76; P = 0.0021) and<br /><span style='background:#90ee90'>ORR</span> (35 vs. <span style='background:#ffc0cb'>19</span><span style='background:#ffc0cb'>%</span>) over capecitabine alone. Corresponding</td></tr>\n",
       "<tr><td>21128114.txt</td><td>alone. Corresponding results in patients with <br />high performance status (KPS 90-100) were median OS of 16.7 versus 16.2 months<br />(HR, 0.98; P = 0.8111), median PFS of 6.0 versus 4.4 months (HR, 0.58;<br />P = 0.0009), and <span style='background:#90ee90'>ORR</span> of 45 versus <span style='background:#ffc0cb'>28</span><span style='background:#ffc0cb'>%</span>. The</td></tr>\n",
       "<tr><td>17963264.txt</td><td>B. The <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> was <span style='background:#ffc0cb'>59</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>4</span><span style='background:#ffc0cb'>%</span>, comparable to younger<br />patients (<span style='background:#ffc0cb'>59</span><span style='background:#ffc0cb'>%</span>). Median</td></tr>\n",
       "<tr><td>21188390.txt</td><td>). Overall radiological response rate (<span style='background:#90ee90'>ORR</span>), overall survival (OS), and<br />toxicity were assessed as secondary outcomes.<br />RESULTS</td></tr>\n",
       "<tr><td>21188390.txt</td><td>). With regard to <span style='background:#90ee90'>ORR</span>, only VGP -634 was<br />significantly associated with response (G/G vs. G</td></tr>\n",
       "<tr><td>19287023.txt</td><td>toxicity. The primary endpoint was objective response rate (<span style='background:#90ee90'>ORR</span>) per<br />modified Response Evaluation Criteria in Solid Tumors (RECIST) by independent<br />central review. Secondary</td></tr>\n",
       "<tr><td>19287023.txt</td><td>panitumumab. Seven<br />patients had partial responses for a confirmed <span style='background:#90ee90'>ORR</span> of <span style='background:#ffc0cb'>13</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>5</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI: 5.6, 25.8). <br />Median</td></tr>\n",
       "<tr><td>18034592.txt</td><td>control. In addition, more limited noncomparative data from a large trial<br />indicated a <span style='background:#ffc0cb'>13</span><span style='background:#ffc0cb'>%</span> overall objective response rate (<span style='background:#90ee90'>ORR</span>) in platinum-refractory<br />patients with SCCHN. In</td></tr>\n",
       "<tr><td>18034592.txt</td><td>SCCHN. In patients with EGFR-expressing mCRC, cetuximab plus<br />irinotecan improved <span style='background:#90ee90'>ORR</span> more than cetuximab monotherapy in a trial in<br />irinotecan-refractory patients; however, there was no difference in overall<br />survival (OS) between cetuximab plus irinotecan and cetuximab monotherapy in<br />oxaliplatin-refractory recipients in another trial. In</td></tr>\n",
       "<tr><td>19652060.txt</td><td>daily. A one-arm, single-stage design was used to estimate the primary end <br />point of objective response rate (<span style='background:#90ee90'>ORR</span>), defined by RECIST (Response Evaluation<br />Criteria in Solid Tumors). Secondary</td></tr>\n",
       "<tr><td>19652060.txt</td><td>daily. In 62 patients<br />evaluable for response, the <span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>22</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>6</span><span style='background:#ffc0cb'>%</span>, and the median duration of response<br />was 17.5 months. Median</td></tr>\n",
       "<tr><td>21937232.txt</td><td>MBC. Analysis<br />included progression-free survival (PFS), overall survival (OS), objective<br />response rate (<span style='background:#90ee90'>ORR</span>) and toxicity.<br />RESULTS</td></tr>\n",
       "<tr><td>21937232.txt</td><td>vs. 2.8 months; hazard<br />ratio, 0.58; p < 0.0001), <span style='background:#90ee90'>ORR</span> (<span style='background:#ffc0cb'>46</span><span style='background:#ffc0cb'>%</span> vs. <span style='background:#ffc0cb'>24</span><span style='background:#ffc0cb'>%</span>) and OS (median: 15.1 months vs. 12</td></tr>\n",
       "<tr><td>11956647.txt</td><td>treatment.<br />After 6 weeks, 30 patients were assessable for response: no CR was observed, a PR<br />was achieved in 15 patients (<span style='background:#ffc0cb'>50</span><span style='background:#ffc0cb'>%</span>; <span style='background:#90ee90'>ORR</span> <span style='background:#ffc0cb'>50</span><span style='background:#ffc0cb'>%</span>). After</td></tr>\n",
       "<tr><td>11956647.txt</td><td>). After 15 weeks, 1 CR and 8 PR were<br />observed (<span style='background:#90ee90'>ORR</span> <span style='background:#ffc0cb'>30</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>0</span><span style='background:#ffc0cb'>%</span>). The</td></tr>\n",
       "<tr><td>11956647.txt</td><td>death. The <span style='background:#ffc0cb'>30</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>0</span><span style='background:#ffc0cb'>%</span> <span style='background:#90ee90'>ORR</span>, the 15 month OS and the 10 month PFS obtained in this<br />study are comparable with those observed with cisplatin plus epirubicin (<span style='background:#90ee90'>ORR</span><br /><span style='background:#ffc0cb'>39</span><span style='background:#ffc0cb'>-</span><span style='background:#ffc0cb'>54</span><span style='background:#ffc0cb'>%</span>) in phase II studies and in a previous phase III study (<span style='background:#90ee90'>ORR</span> <span style='background:#ffc0cb'>33</span><span style='background:#ffc0cb'>%</span>, OS 10.5<br />months). Moreover</td></tr>\n",
       "<tr><td>21135284.txt</td><td>). The primary efficacy end point was <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span><br />for amrubicin. Secondary</td></tr>\n",
       "<tr><td>21135284.txt</td><td>topotecan. Amrubicin<br />treatment resulted in a significantly higher <span style='background:#90ee90'>ORR</span> than topotecan (<span style='background:#ffc0cb'>44</span><span style='background:#ffc0cb'>%</span> v <span style='background:#ffc0cb'>15</span><span style='background:#ffc0cb'>%</span>; P =<br />.021</td></tr>\n",
       "<tr><td>21135284.txt</td><td>).<br />CONCLUSION: Amrubicin shows promising activity, with an <span style='background:#90ee90'>ORR</span> of <span style='background:#ffc0cb'>44</span><span style='background:#ffc0cb'>%</span> compared with <br />an <span style='background:#90ee90'>ORR</span> of <span style='background:#ffc0cb'>15</span><span style='background:#ffc0cb'>%</span> for topotecan as second-line treatment in patients with SCLC<br />sensitive to first-line platinum-based chemotherapy. In</td></tr>\n",
       "<tr><td>20306116.txt</td><td>rest. The <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> for all patients was <span style='background:#ffc0cb'>19</span><span style='background:#ffc0cb'>%</span>. Similarly</td></tr>\n",
       "<tr><td>20306116.txt</td><td><span style='background:#ffc0cb'>%</span>. Similarly, the<br /><span style='background:#90ee90'>ORR</span> for frail and elderly patients was <span style='background:#ffc0cb'>22</span><span style='background:#ffc0cb'>%</span> and <span style='background:#ffc0cb'>18</span><span style='background:#ffc0cb'>%</span>, respectively. Median</td></tr>\n",
       "<tr><td>20089562.txt</td><td>). The primary end point was objective response<br />rate (<span style='background:#90ee90'>ORR</span>). Secondary</td></tr>\n",
       "<tr><td>20089562.txt</td><td>safety.<br />RESULTS: <span style='background:#90ee90'>ORR</span> for patients randomly assigned to receive EC and ED were <span style='background:#ffc0cb'>42</span><span style='background:#ffc0cb'>%</span> and<br /><span style='background:#ffc0cb'>47</span><span style='background:#ffc0cb'>%</span>, respectively (P = 0.63). Median</td></tr>\n",
       "<tr><td>21803002.txt</td><td>). Secondary endpoints included progression-free<br />survival (PFS), overall survival (OS), objective response rate (<span style='background:#90ee90'>ORR</span>), and safety.<br />RESULTS</td></tr>\n",
       "<tr><td>21803002.txt</td><td>). The DCR was <span style='background:#ffc0cb'>87</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI, <span style='background:#ffc0cb'>77</span><span style='background:#ffc0cb'>%</span><span style='background:#ffc0cb'>-</span><span style='background:#ffc0cb'>97</span><span style='background:#ffc0cb'>%</span>); <span style='background:#90ee90'>ORR</span><br />was <span style='background:#ffc0cb'>32</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI, <span style='background:#ffc0cb'>19</span><span style='background:#ffc0cb'>%</span><span style='background:#ffc0cb'>-</span><span style='background:#ffc0cb'>46</span><span style='background:#ffc0cb'>%</span>). Median</td></tr>\n",
       "<tr><td>21472713.txt</td><td>treatment. This<br />regimen produced 1 complete response, 3 partial responses (<span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span> <br />[<span style='background:#90ee90'>ORR</span>], <span style='background:#ffc0cb'>13</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>8</span><span style='background:#ffc0cb'>%</span>), and 10 cases of stable disease among 29 evaluable patients. For</td></tr>\n",
       "<tr><td>21472713.txt</td><td>respectively.<br />Patients with platinum-resistant disease achieved an <span style='background:#90ee90'>ORR</span> of <span style='background:#ffc0cb'>22</span><span style='background:#ffc0cb'>%</span>, with a median<br />PFS of 5.6 months and a median OS of 23 months. The</td></tr>\n",
       "<tr><td>20212251.txt</td><td>rate. Secondary end<br />points included <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span>, progression-free survival (PFS),<br />overall survival (OS), and treatment-related toxicity. RESULTS</td></tr>\n",
       "<tr><td>20212251.txt</td><td>analysis. The CR and <span style='background:#90ee90'>ORR</span> reached <span style='background:#ffc0cb'>47</span><span style='background:#ffc0cb'>%</span> and <span style='background:#ffc0cb'>88</span><span style='background:#ffc0cb'>%</span> in the CC arm and <span style='background:#ffc0cb'>46</span><span style='background:#ffc0cb'>%</span> and <span style='background:#ffc0cb'>82</span><span style='background:#ffc0cb'>%</span> in the<br />FC arm (P = .25</td></tr>\n",
       "<tr><td>21908069.txt</td><td>months. The primary endpoint<br />was the <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span> (CR+PR) according to RECIST. Secondary</td></tr>\n",
       "<tr><td>21908069.txt</td><td>response. Partial response was seen in 29/67 patients corresponding<br />to an <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> of <span style='background:#ffc0cb'>43</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span>CI, 28.5-53.7). No</td></tr>\n",
       "<tr><td>21298496.txt</td><td>drugs. Based on an<br />intention-to-treat analysis, 60 patients were assessable for responses and 11<br />patients achieved a partial response (PR), giving an <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> <br />of <span style='background:#ffc0cb'>18</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>%</span>. Twenty</td></tr>\n",
       "<tr><td>16844257.txt</td><td>cycles. Primary endpoint was <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span>,<br />secondary endpoints were progression-free (PFS) and overall survival (OS), and<br />safety.<br />RESULTS</td></tr>\n",
       "<tr><td>16844257.txt</td><td>metastases. In 27 evaluable patients with follow-up, there were 10 partial <br />responses for an <span style='background:#90ee90'>ORR</span> of <span style='background:#ffc0cb'>37</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>90</span><span style='background:#ffc0cb'>%</span> confidence interval [CI], <span style='background:#ffc0cb'>22</span><span style='background:#ffc0cb'>-</span><span style='background:#ffc0cb'>55</span><span style='background:#ffc0cb'>%</span>). Median</td></tr>\n",
       "<tr><td>20682548.txt</td><td>). Secondary end points were<br />progression-free survival (PFS), objective response rates (<span style='background:#90ee90'>ORR</span>) and toxicity.<br />RESULTS</td></tr>\n",
       "<tr><td>20682548.txt</td><td>toxicity.<br />RESULTS: Neither OS [arm A: 7.8 (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI: 4.2-11.4), arm B: 8.0 (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI: 4.9-11.1)<br />months] and PFS [arm A: 4.0 (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI: 0-8.0), arm B: 3.1 (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI: 1.9-4.2) months]<br />nor <span style='background:#90ee90'>ORR</span> (arm A: <span style='background:#ffc0cb'>37</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>5</span><span style='background:#ffc0cb'>%</span>, arm B: <span style='background:#ffc0cb'>41</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>5</span><span style='background:#ffc0cb'>%</span>) were significantly different. On</td></tr>\n",
       "<tr><td>16086886.txt</td><td>vs.<span style='background:#ffc0cb'>13</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>04</span><span style='background:#ffc0cb'>%</span>, P=0.003); significant differences were found <br />in <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> (<span style='background:#ffc0cb'>60</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>86</span><span style='background:#ffc0cb'>%</span> vs. <span style='background:#ffc0cb'>30</span></td></tr>\n",
       "<tr><td>21300933.txt</td><td>). The<br />primary study end point was objective response rate (<span style='background:#90ee90'>ORR</span>).<br />RESULTS</td></tr>\n",
       "<tr><td>21300933.txt</td><td>).<br />RESULTS: In the intention-to-treat patient population (n = 177), <span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>46</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span><br />CI, 35 to 57) for CAPIRI plus cetuximab versus <span style='background:#ffc0cb'>48</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI, 37 to 59) for CAPOX<br />plus cetuximab. Analysis</td></tr>\n",
       "<tr><td>21300933.txt</td><td>population. Patients with KRAS wild-type in the CAPIRI <br />plus cetuximab arm showed an <span style='background:#90ee90'>ORR</span> of <span style='background:#ffc0cb'>50</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>0</span><span style='background:#ffc0cb'>%</span>, a PFS of 6.2 months and an OS of 21.1 <br />months. In</td></tr>\n",
       "<tr><td>21300933.txt</td><td>months. In the CAPOX plus cetuximab arm, an <span style='background:#90ee90'>ORR</span> of <span style='background:#ffc0cb'>44</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>9</span><span style='background:#ffc0cb'>%</span>, a PFS of 7.1 months and<br />an OS of 23.5 months were observed. While</td></tr>\n",
       "<tr><td>21300933.txt</td><td>observed. While <span style='background:#90ee90'>ORR</span> and PFS were comparable in KRAS<br />wild-type and mutant subgroups, a trend toward longer survival was associated<br />with KRAS wild-type. Both</td></tr>\n",
       "<tr><td>21750555.txt</td><td>). Secondary endpoints included overall survival<br />(OS), objective response rate (<span style='background:#90ee90'>ORR</span>), adverse events, and pharmacokinetics.<br />RESULTS</td></tr>\n",
       "<tr><td>21750555.txt</td><td>groups. In the dacarbazine+placebo, dacarbazine+intetumumab, 10 mg kg(-1)<br />intetumumab, and 5 mg kg(-1) intetumumab groups, median PFS was 1.8, 2.5, 1.4,<br />and 1.4 months; median OS was 8, 11, 15, and 9.8 months; and <span style='background:#90ee90'>ORR</span> of<br />complete+partial response was 10, 3, 6, and <span style='background:#ffc0cb'>0</span><span style='background:#ffc0cb'>%</span>. Nonlinear</td></tr>\n",
       "<tr><td>19605504.txt</td><td>). The primary end point<br />was <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> and secondary end points included<br />progression-free survival (PFS), overall survival (OS) and safety.<br />RESULTS</td></tr>\n",
       "<tr><td>19605504.txt</td><td>analysis. In the XI and XP treatment arms, there were no marked<br />differences in <span style='background:#90ee90'>ORR</span>, <span style='background:#ffc0cb'>37</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>7</span><span style='background:#ffc0cb'>%</span> versus <span style='background:#ffc0cb'>42</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>0</span><span style='background:#ffc0cb'>%</span>, and median PFS, 4.2 versus 4.8 months,<br />although median OS was longer, 10.2 versus 7.9 months, respectively. Grade</td></tr>\n",
       "<tr><td>21585693.txt</td><td>rituximab. The <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> was <span style='background:#ffc0cb'>29</span><span style='background:#ffc0cb'>%</span>; <span style='background:#ffc0cb'>46</span><span style='background:#ffc0cb'>%</span> (three<br />complete responses, two partial responses (PR) for patients with low grade B-cell<br />NHL (LGL) and <span style='background:#ffc0cb'>9</span><span style='background:#ffc0cb'>%</span> (one PR) for patients with diffuse large B-cell lymphoma<br />(DLBCL). After</td></tr>\n",
       "<tr><td>21249514.txt</td><td>). We evaluated<br />objective response rate (<span style='background:#90ee90'>ORR</span>), progression free survival (PFS), overall survival <br />(OS), and toxicity profiles.<br />RESULTS</td></tr>\n",
       "<tr><td>21249514.txt</td><td>). <span style='background:#90ee90'>ORR</span> and<br />disease control rate for sorafenib were <span style='background:#ffc0cb'>2</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>%</span> and <span style='background:#ffc0cb'>52</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>%</span> vs <span style='background:#ffc0cb'>6</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>2</span><span style='background:#ffc0cb'>%</span> and <span style='background:#ffc0cb'>43</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>4</span><span style='background:#ffc0cb'>%</span> for CTX.<br />CTX</td></tr>\n",
       "<tr><td>19273714.txt</td><td>). Overall response rate (<span style='background:#90ee90'>ORR</span>) was <span style='background:#ffc0cb'>32</span><span style='background:#ffc0cb'>%</span> in both arms, and<br />overall survival (OS) was not different between arms (P = .983</td></tr>\n",
       "<tr><td>19273714.txt</td><td>).<br />CONCLUSION: No difference was observed between GD and CD arms in PFS, <span style='background:#90ee90'>ORR</span>, and<br />OS. TTF</td></tr>\n",
       "<tr><td>21464406.txt</td><td>). Secondary end points included overall survival<br />(OS) and <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span>.<br />RESULTS</td></tr>\n",
       "<tr><td>21464406.txt</td><td><span style='background:#90ee90'>)</span>.<br />RESULTS: PFS, OS, and <span style='background:#90ee90'>ORR</span> were not statistically improved with PTK/ZK (P > .05</td></tr>\n",
       "<tr><td>20564642.txt</td><td>cycles. The <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'><br /></span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> was <span style='background:#ffc0cb'>91</span><span style='background:#ffc0cb'>%</span>, which included a greater than or equal to very good partial<br />response (> or = VGPR) rate of <span style='background:#ffc0cb'>57</span><span style='background:#ffc0cb'>%</span> (including <span style='background:#ffc0cb'>20</span><span style='background:#ffc0cb'>%</span> stringent complete<br />responses/complete response [sCR/CR] rate). In</td></tr>\n",
       "<tr><td>20564642.txt</td><td>). In front-line patients, the <span style='background:#90ee90'>ORR</span> was<br /><span style='background:#ffc0cb'>94</span><span style='background:#ffc0cb'>%</span>, which included a <span style='background:#ffc0cb'>56</span><span style='background:#ffc0cb'>%</span> > or = VGPR rate (<span style='background:#ffc0cb'>24</span><span style='background:#ffc0cb'>%</span> sCR/CR). The</td></tr>\n",
       "<tr><td>20564642.txt</td><td>kg. The <span style='background:#90ee90'>ORR</span> after ASCT in 34 patients who <br />were evaluable for response was <span style='background:#ffc0cb'>100</span><span style='background:#ffc0cb'>%</span>, including a <span style='background:#ffc0cb'>76</span><span style='background:#ffc0cb'>%</span> > or = VGPR rate (<span style='background:#ffc0cb'>53</span><span style='background:#ffc0cb'>%</span><br />sCR/CR). Among</td></tr>\n",
       "<tr><td>18720480.txt</td><td>nausea. The <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> was <span style='background:#ffc0cb'>16</span><span style='background:#ffc0cb'>%</span><br />and included 3 complete responses that lasted 10.8 months, > or =32 months, and ><br />or =36 months and 2 partial responses that lasted 13 months and 14 months.<br />Responses</td></tr>\n",
       "<tr><td>18604722.txt</td><td>chemotherapy. The <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> to<br />salvage chemotherapy (<span style='background:#ffc0cb'>25</span><span style='background:#ffc0cb'>%</span> vs. <span style='background:#ffc0cb'>48</span><span style='background:#ffc0cb'>%</span>, p = 0.01) and 2-year OS after diagnosis of RR <br />disease (<span style='background:#ffc0cb'>15</span><span style='background:#ffc0cb'>%</span> vs. <span style='background:#ffc0cb'>34</span><span style='background:#ffc0cb'>%</span>, p = 0.018) was inferior in PMLCL patients. The</td></tr>\n",
       "<tr><td>18604722.txt</td><td>similar. RR PMLCL had an inferior <span style='background:#90ee90'>ORR</span> and survival compared with DLBCL but<br />chemosensitive PMLCL and DLBCL patients have similar outcomes post-ASCT.<br />Strategies</td></tr>\n",
       "<tr><td>21576636.txt</td><td>bevacizumab. Treatment efficacy, measured by progression-free<br />survival (PFS) and <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span>, was compared. Treatment</td></tr>\n",
       "<tr><td>21576636.txt</td><td>similar. <span style='background:#90ee90'>ORR</span>s for<br />sorafenib/erlotinib and placebo/erlotinib were <span style='background:#ffc0cb'>8</span><span style='background:#ffc0cb'>%</span> and <span style='background:#ffc0cb'>11</span><span style='background:#ffc0cb'>%</span>, respectively (P =<br />.56</td></tr>\n",
       "<tr><td>20581887.txt</td><td>4. Overall response rate (<span style='background:#90ee90'>ORR</span>)<br />consisting of complete response and partial response (CR+PR, PFS, OS and toxicity<br />are reported. Between</td></tr>\n",
       "<tr><td>20581887.txt</td><td>disease. <span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>85</span><span style='background:#ffc0cb'>%</span> (CR <span style='background:#ffc0cb'>12</span><span style='background:#ffc0cb'>%</span>, very good PR <span style='background:#ffc0cb'>43</span><span style='background:#ffc0cb'>%</span> and PR <span style='background:#ffc0cb'>30</span><span style='background:#ffc0cb'>%</span>).<br />Median</td></tr>\n",
       "<tr><td>21728023.txt</td><td>refusal. The primary efficacy endpoint was best <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'><br /></span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> post baseline. The</td></tr>\n",
       "<tr><td>21728023.txt</td><td>efficacy. Two complete responses and 12 partial responses were<br />observed for an <span style='background:#90ee90'>ORR</span> of <span style='background:#ffc0cb'>25</span><span style='background:#ffc0cb'>%</span>. The</td></tr>\n",
       "<tr><td>19628292.txt</td><td>). The primary objective was<br />objective response rate (<span style='background:#90ee90'>ORR</span>). Secondary</td></tr>\n",
       "<tr><td>19628292.txt</td><td>Gem. Efficacy was assessed in<br />patients who completed at least 1 cycle of treatment; <span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>31</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>7</span><span style='background:#ffc0cb'>%</span> in arm A<br />versus <span style='background:#ffc0cb'>25</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>6</span><span style='background:#ffc0cb'>%</span> in arm B and DCR was <span style='background:#ffc0cb'>70</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>7</span><span style='background:#ffc0cb'>%</span> versus <span style='background:#ffc0cb'>56</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>4</span><span style='background:#ffc0cb'>%</span>, respectively. A</td></tr>\n",
       "<tr><td>19451710.txt</td><td>weeks. The primary endpoint was <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> and secondary<br />endpoints were progression-free survival (PFS), overall survival (OS) and<br />toxicity.<br />RESULTS</td></tr>\n",
       "<tr><td>19451710.txt</td><td>). One complete response (<span style='background:#ffc0cb'>2</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>1</span><span style='background:#ffc0cb'>%</span>) and 19 partial responses (<span style='background:#ffc0cb'>39</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>6</span><span style='background:#ffc0cb'>%</span>) were<br />noted, resulting in an <span style='background:#90ee90'>ORR</span> of <span style='background:#ffc0cb'>41</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>7</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> confidence interval, CI: 27.<span style='background:#ffc0cb'>7</span><span style='background:#ffc0cb'>-</span><span style='background:#ffc0cb'>55</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>6</span><span style='background:#ffc0cb'>%</span>) by <br />intent-to-treat analysis. With</td></tr>\n",
       "<tr><td>20066161.txt</td><td>LMS. The <span style='background:#90ee90'>overall</span><span style='background:#90ee90'><br /></span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> was <span style='background:#ffc0cb'>18</span><span style='background:#ffc0cb'>%</span>; and the median progression-free (PFS) and overall<br />survival (OS) were 3.8 and 9.7 months respectively. No</td></tr>\n",
       "<tr><td>20580219.txt</td><td>). The <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> of mutant KRAS<br />patients was <span style='background:#ffc0cb'>14</span><span style='background:#ffc0cb'>%</span> (119/829), whereas the <span style='background:#90ee90'>ORR</span> of wild-type KRAS patients was <span style='background:#ffc0cb'>39</span><span style='background:#ffc0cb'>%</span><br />(529/1359). The</td></tr>\n",
       "<tr><td>20580219.txt</td><td>). The overall pooled relative ratio (RR) for <span style='background:#90ee90'>ORR</span> was 0.24 (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span><br />confidence intervals (CI): 0.16-0.38; P<0.01) when mutant KRAS patients were<br />compared with wild-type KRAS patients. Median</td></tr>\n",
       "<tr><td>19861580.txt</td><td>unknown. This study aimed to<br />evaluate the incidence of CEA flare and its impact on objective response rate<br />(<span style='background:#90ee90'>ORR</span>), progression-free survival (PFS) and overall survival (OS).<br />PATIENTS</td></tr>\n",
       "<tr><td>19861580.txt</td><td>patients. On multivariate<br />analysis, compared with patients with increasing CEA, patients with CEA flare had<br />a significantly better <span style='background:#90ee90'>ORR</span> [I versus F: <span style='background:#ffc0cb'>11</span><span style='background:#ffc0cb'>%</span> versus <span style='background:#ffc0cb'>73</span><span style='background:#ffc0cb'>%</span>; risk ratio (RR): 27.96;<br /><span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> confidence interval (CI): 9.55-81.88; P < 0.001], PFS (median 3.1 versus 8.3 <br />months; RR: 0.38; <span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI: 0.26-0.56; P < 0.001) and OS (median 10.9 versus 17.7<br />months; RR: 0.53; <span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI: 0.34-0.82; P < 0.001).<br />CONCLUSIONS</td></tr>\n",
       "<tr><td>21697017.txt</td><td>days. The primary endpoint was CNS objective response rate (<span style='background:#90ee90'>ORR</span>).<br />Secondary</td></tr>\n",
       "<tr><td>21697017.txt</td><td>radiotherapy. Two patients achieved a partial response (<span style='background:#90ee90'>ORR</span>, <span style='background:#ffc0cb'>13</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>%</span>)<br />and remained in the study for 6 cycles. Responses</td></tr>\n",
       "<tr><td>22000696.txt</td><td>status.<br />RESULTS: In an intention-to-treat analysis, the <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> was<br /><span style='background:#ffc0cb'>24</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>5</span><span style='background:#ffc0cb'>%</span>. The</td></tr>\n",
       "<tr><td>22000696.txt</td><td>mutations. The <span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>66</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>7</span><span style='background:#ffc0cb'>%</span> in patients with activating EGFR<br />mutations and <span style='background:#ffc0cb'>14</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>8</span><span style='background:#ffc0cb'>%</span> in patients with wild-type EGFR (2P = .006</td></tr>\n",
       "<tr><td>20385980.txt</td><td>). The primary end point was <br /><span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span>; secondary end points included progression-free<br />survival (PFS), overall survival (OS), and change in left ventricular ejection<br />fraction (LVEF).<br />RESULTS</td></tr>\n",
       "<tr><td>20385980.txt</td><td>). The <span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>21</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI, <span style='background:#ffc0cb'>12</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>7</span><span style='background:#ffc0cb'>%</span><br />to <span style='background:#ffc0cb'>32</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>%</span>), with one complete response (<span style='background:#ffc0cb'>1</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>%</span>) and 15 partial responses (<span style='background:#ffc0cb'>20</span><span style='background:#ffc0cb'>%</span>).<br />Median</td></tr>\n",
       "<tr><td>20385980.txt</td><td>respectively. The <span style='background:#90ee90'>ORR</span> in 43 patients who never responded <br />to first-line therapy was <span style='background:#ffc0cb'>16</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI, <span style='background:#ffc0cb'>6</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>8</span><span style='background:#ffc0cb'>%</span> to <span style='background:#ffc0cb'>30</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>7</span><span style='background:#ffc0cb'>%</span>). Most</td></tr>\n",
       "<tr><td>20385980.txt</td><td>).<br />CONCLUSION: Single-agent amrubicin showed promising activity with a <span style='background:#ffc0cb'>21</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>%</span> <span style='background:#90ee90'>ORR</span> and<br />an acceptable safety profile when used as second-line therapy patients with<br />platinum-refractory SCLC. Amrubicin</td></tr>\n",
       "<tr><td>19804901.txt</td><td>months. The <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'><br /></span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> was <span style='background:#ffc0cb'>60</span><span style='background:#ffc0cb'>%</span> (CR <span style='background:#ffc0cb'>25</span><span style='background:#ffc0cb'>%</span> and PR <span style='background:#ffc0cb'>35</span><span style='background:#ffc0cb'>%</span>). Median</td></tr>\n",
       "<tr><td>21070370.txt</td><td>patient. The <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> was<br /><span style='background:#ffc0cb'>90</span><span style='background:#ffc0cb'>%</span>, with a complete response rate (CRR) of <span style='background:#ffc0cb'>70</span><span style='background:#ffc0cb'>%</span>. Estimated</td></tr>\n",
       "<tr><td>20646647.txt</td><td>OS. The <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'><br /></span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> of 182 patients was <span style='background:#ffc0cb'>69</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>2</span><span style='background:#ffc0cb'>%</span> and median OS and PFS were 49.0+/-5.0 and<br />19.0+/-2.1 months, respectively. The</td></tr>\n",
       "<tr><td>20646647.txt</td><td>respectively. Compared with those not receiving thalidomide induction, the<br />patients on a VAD-like regimen combined with thalidomide showed a superior <span style='background:#90ee90'>ORR</span><br />(<span style='background:#ffc0cb'>81</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>5</span><span style='background:#ffc0cb'>%</span> vs <span style='background:#ffc0cb'>59</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>7</span><span style='background:#ffc0cb'>%</span>, P=0.008), a longer OS (79.0+/-29.5 vs 37.0+/-4.8 months,<br />P=0.001) and a longer PFS (24.0+/-6.0 vs 14.0+/-2.7 months, P=0.033).<br />CONCLUSION</td></tr>\n",
       "<tr><td>20646647.txt</td><td>reliable. Induction therapy including thalidomide can not only improve the<br /><span style='background:#90ee90'>ORR</span>, but also delay the relapse or progression of disease. It</td></tr>\n",
       "<tr><td>21321086.txt</td><td>). The primary end point was <span style='background:#90ee90'>ORR</span> (per RECIST). Other</td></tr>\n",
       "<tr><td>21321086.txt</td><td>).<br />RESULTS: <span style='background:#90ee90'>ORR</span>s in the three arms were as follows: arm A, <span style='background:#ffc0cb'>30</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> confidence<br />interval <span style='background:#ffc0cb'>18</span><span style='background:#ffc0cb'>%</span> to <span style='background:#ffc0cb'>43</span><span style='background:#ffc0cb'>%</span>); arm B, <span style='background:#ffc0cb'>23</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>13</span><span style='background:#ffc0cb'>%</span> to <span style='background:#ffc0cb'>36</span><span style='background:#ffc0cb'>%</span>); and arm C, <span style='background:#ffc0cb'>37</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>25</span><span style='background:#ffc0cb'>%</span> to <span style='background:#ffc0cb'>50</span><span style='background:#ffc0cb'>%</span>).<br />Median</td></tr>\n",
       "<tr><td>20593498.txt</td><td>).<br />RESULTS: No significant difference was found between treatment arms A and B in<br />the progression-free survival (PFS) rate at 9 mo, <span style='background:#ffc0cb'>45</span><span style='background:#ffc0cb'>%</span> vs <span style='background:#ffc0cb'>34</span><span style='background:#ffc0cb'>%</span>; median PFS, 8.6 mo <br />vs 8.3 mo [hazard ratio (HR) = 1.06]; <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> <span style='background:#ffc0cb'>43</span><span style='background:#ffc0cb'>%</span> vs <span style='background:#ffc0cb'>45</span><span style='background:#ffc0cb'>%</span><br />[odds ratio (OR) = 0.93] and median overall survival (OS), 17.4 mo vs 18.9 mo (HR<br />= 0.98). Patients</td></tr>\n",
       "<tr><td>20593498.txt</td><td>). Patients with KRAS wild-type tumors demonstrated improved PFS (HR =<br />0.55, P = 0.0051), OS, (HR = 0.62, P = 0.0296) and <span style='background:#90ee90'>ORR</span> (<span style='background:#ffc0cb'>53</span><span style='background:#ffc0cb'>%</span> vs <span style='background:#ffc0cb'>36</span><span style='background:#ffc0cb'>%</span>) and in arm A,<br />improved PFS (HR = 0.49, P = 0.0196), OS (HR = 0.48, P = 0.0201) and <span style='background:#90ee90'>ORR</span> (<span style='background:#ffc0cb'>56</span><span style='background:#ffc0cb'>%</span> vs <br /><span style='background:#ffc0cb'>30</span><span style='background:#ffc0cb'>%</span>), compared with patients with KRAS mutated tumors. In</td></tr>\n",
       "<tr><td>20723384.txt</td><td>toxicity.<br />RESULTS: Among a total of 28 patients, the objective response rate (<span style='background:#90ee90'>ORR</span>) of<br />erlotinib was <span style='background:#ffc0cb'>28</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>6</span><span style='background:#ffc0cb'>%</span>. The</td></tr>\n",
       "<tr><td>19687333.txt</td><td>cycles. The primary end point was objective tumor response rate (<span style='background:#90ee90'>ORR</span>). <br />Secondary</td></tr>\n",
       "<tr><td>19687333.txt</td><td>155. Two patients achieved a confirmed <br />partial response, with an <span style='background:#90ee90'>ORR</span> of <span style='background:#ffc0cb'>5</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>4</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI, <span style='background:#ffc0cb'>0</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>7</span><span style='background:#ffc0cb'>%</span> to <span style='background:#ffc0cb'>18</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>2</span><span style='background:#ffc0cb'>%</span>). An</td></tr>\n",
       "<tr><td>20973869.txt</td><td>respectively. The primary<br />end-point was the objective response rate (<span style='background:#90ee90'>ORR</span>) and the secondary end-points<br />included clinical benefit, progression-free survival (PFS), overall survival (OS)<br />and safety. Median</td></tr>\n",
       "<tr><td>20973869.txt</td><td>months. Complete response (CR) was observed<br />in four patients (<span style='background:#ffc0cb'>8</span><span style='background:#ffc0cb'>%</span>) and partial response in seven (<span style='background:#ffc0cb'>14</span><span style='background:#ffc0cb'>%</span>), yielding an <span style='background:#90ee90'>ORR</span> of<br /><span style='background:#ffc0cb'>22</span><span style='background:#ffc0cb'>%</span>. None</td></tr>\n",
       "<tr><td>20973869.txt</td><td>up. The <span style='background:#90ee90'>ORR</span> were <span style='background:#ffc0cb'>17</span><span style='background:#ffc0cb'>%</span> in the favorable- or intermediate-risk group<br />and <span style='background:#ffc0cb'>40</span><span style='background:#ffc0cb'>%</span> in the poor-risk group. The</td></tr>\n",
       "<tr><td>19862815.txt</td><td>daily. Primary endpoints included the<br />objective response rate (<span style='background:#90ee90'>ORR</span>) and safety. Secondary</td></tr>\n",
       "<tr><td>19862815.txt</td><td>). The <span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>30</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> confidence interval [CI],<br /><span style='background:#ffc0cb'>16</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>6</span><span style='background:#ffc0cb'>%</span><span style='background:#ffc0cb'>-</span><span style='background:#ffc0cb'>46</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>5</span><span style='background:#ffc0cb'>%</span>) in the sorafenib arm and <span style='background:#ffc0cb'>25</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI, <span style='background:#ffc0cb'>12</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>7</span><span style='background:#ffc0cb'>%</span><span style='background:#ffc0cb'>-</span><span style='background:#ffc0cb'>41</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>2</span><span style='background:#ffc0cb'>%</span>) in the<br />combination arm. The</td></tr>\n",
       "<tr><td>19533023.txt</td><td>use.<br />The primary end point was objective response rate (<span style='background:#90ee90'>ORR</span>). Secondary</td></tr>\n",
       "<tr><td>19533023.txt</td><td>failure. Low MGMT expression, compared with<br />high MGMT expression, showed no significant difference in <span style='background:#90ee90'>ORR</span> (25 vs. <span style='background:#ffc0cb'>8</span><span style='background:#ffc0cb'>%</span>), median<br />PFS (14 vs. 5 months) or OS (21 vs. 15 months). Although</td></tr>\n",
       "<tr><td>21163071.txt</td><td>collected. The cumulative survival rate, objective response rate (<span style='background:#90ee90'>ORR</span>), disease<br />control rate (DCR), progression free survival (PFS) of the cases were calculated.<br />The</td></tr>\n",
       "<tr><td>21163071.txt</td><td>calculated.<br />The difference in <span style='background:#90ee90'>ORR</span>, DCR, PFS and oval survival (OS) between the regimens used <br />as first-line and non-first-line treatment, and between the regimens including<br />oxaliplatin and irinotecan were compared.<br />RESULTS</td></tr>\n",
       "<tr><td>21163071.txt</td><td>compared.<br />RESULTS: The overall <span style='background:#90ee90'>ORR</span> of cetuximab plus chemotherapy was <span style='background:#ffc0cb'>43</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>1</span><span style='background:#ffc0cb'>%</span>, DCR <span style='background:#ffc0cb'>73</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>5</span><span style='background:#ffc0cb'>%</span>,<br />median PFS 4.0 months, OS 28.5 months, and the 1-year, 3-year, and 5-year<br />survival rate was <span style='background:#ffc0cb'>89</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>2</span><span style='background:#ffc0cb'>%</span>, <span style='background:#ffc0cb'>50</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>9</span><span style='background:#ffc0cb'>%</span> and <span style='background:#ffc0cb'>27</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>5</span><span style='background:#ffc0cb'>%</span>, respectively. The</td></tr>\n",
       "<tr><td>21163071.txt</td><td>respectively. The differences in <span style='background:#90ee90'>ORR</span><br />(<span style='background:#ffc0cb'>50</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>0</span><span style='background:#ffc0cb'>%</span> vs. <span style='background:#ffc0cb'>40</span></td></tr>\n",
       "<tr><td>21163071.txt</td><td>). The differences in <span style='background:#90ee90'>ORR</span> (<span style='background:#ffc0cb'>54</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>2</span><span style='background:#ffc0cb'>%</span> vs. <span style='background:#ffc0cb'>40</span></td></tr>\n",
       "<tr><td>21163071.txt</td><td>recorded.<br />CONCLUSION: Patients with advanced colorectal cancer and unclear K-ras treated by<br />cetuximab combined with chemotherapy have good <span style='background:#90ee90'>ORR</span> and OS, and the regimen is<br />safe with less adverse events for them. There</td></tr>\n",
       "<tr><td>19652072.txt</td><td>). RECIST-defined objective<br />response rate (<span style='background:#90ee90'>ORR</span>) was the primary end point. Secondary</td></tr>\n",
       "<tr><td>19652072.txt</td><td>). <span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>20</span><span style='background:#ffc0cb'>%</span> with a 7.2-month median response duration. Median</td></tr>\n",
       "<tr><td>19041063.txt</td><td>ASCT. Complete responses (CR) were seen in 12 of 48 patients <br />(<span style='background:#ffc0cb'>25</span><span style='background:#ffc0cb'>%</span>), with an <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span> (<span style='background:#90ee90'>ORR</span> = CR + PR) of <span style='background:#ffc0cb'>85</span><span style='background:#ffc0cb'>%</span>. Median</td></tr>\n",
       "<tr><td>20878159.txt</td><td>months. The <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'><br /></span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> of the first-line chemotherapy was <span style='background:#ffc0cb'>25</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>0</span><span style='background:#ffc0cb'>%</span> with DP (Arm A1) and 13.3<br />with FOLFIRI (Arm B1) (P = 0.322). The</td></tr>\n",
       "<tr><td>20878159.txt</td><td>). The <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span> of second-line chemotherapy<br />was <span style='background:#ffc0cb'>20</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>0</span><span style='background:#ffc0cb'>%</span> with FOLFIRI (Arm A2) and <span style='background:#ffc0cb'>27</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>2</span><span style='background:#ffc0cb'>%</span> with DP (Arm B2) (P = 0.296). The</td></tr>\n",
       "<tr><td>20878159.txt</td><td><span style='background:#ffc0cb'>%</span>.<br />CONCLUSIONS: The <span style='background:#90ee90'>ORR</span>, TCR of Arm A (DP ? FOLFIRI) were not different from those<br />of Arm B (FOLFIRI ? DP). There</td></tr>\n",
       "<tr><td>15857840.txt</td><td>study. Prognostic factors associated with <span style='background:#90ee90'>overall</span><span style='background:#90ee90'><br /></span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span>, progression-free survival (PFS) and overall survival (OS)<br />were identified using univariate and multivariate logistic and/or Cox<br />proportional hazards analyses.<br />RESULTS</td></tr>\n",
       "<tr><td>19887304.txt</td><td>cycles. Primary endpoint was objective<br />response rate (<span style='background:#90ee90'>ORR</span>). Secondary</td></tr>\n",
       "<tr><td>19887304.txt</td><td>). The <span style='background:#90ee90'>ORR</span> was <br /><span style='background:#ffc0cb'>28</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>41</span><span style='background:#ffc0cb'>%</span> and <span style='background:#ffc0cb'>19</span><span style='background:#ffc0cb'>%</span> in patients with TFI >or=6, or <6 months, respectively); rate of<br />disease stabilization was <span style='background:#ffc0cb'>26</span><span style='background:#ffc0cb'>%</span>; response duration and median OS were 6 (2.4-26)<br />and 14 (1-46) months, respectively.<br />CONCLUSION</td></tr>\n",
       "<tr><td>21456002.txt</td><td>melanoma. The primary objective of this phase 2 study <br />was to determine the objective response rate (<span style='background:#90ee90'>ORR</span>) in patients who had received 1<br />previous systemic chemotherapy for unresectable/metastatic melanoma; secondary<br />objectives were to evaluate the clinical response rate (CRR), progression-free<br />survival (PFS), overall survival (OS), duration of response, safety, and<br />pharmacokinetics.<br />METHODS</td></tr>\n",
       "<tr><td>21456002.txt</td><td>). No patients had a complete response (CR), 8 patients had a partial<br />response (PR), and 24 patients had stable disease (SD); the <span style='background:#90ee90'>ORR</span> (CR + PR) was<br /><span style='background:#ffc0cb'>11</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>8</span><span style='background:#ffc0cb'>%</span>, and the CRR (CR + PR + SD) was <span style='background:#ffc0cb'>47</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>1</span><span style='background:#ffc0cb'>%</span>. The</td></tr>\n",
       "<tr><td>22017239.txt</td><td>). Primary endpoint was <span style='background:#90ee90'>overall</span><span style='background:#90ee90'><br /></span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span>. Secondary</td></tr>\n",
       "<tr><td>22017239.txt</td><td>fatigue. <span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>6</span><span style='background:#ffc0cb'>%</span>, median PFS was 2.2 months, and OS 4.3 months. Low</td></tr>\n",
       "<tr><td>19738129.txt</td><td>cycles. Secondary end points included <span style='background:#90ee90'>overall</span><span style='background:#90ee90'><br /></span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span>, progression-free survival (PFS), and overall survival (OS). <br />The</td></tr>\n",
       "<tr><td>19738129.txt</td><td>evaluated.<br />RESULTS: After six cycles, the <span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>85</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>0</span><span style='background:#ffc0cb'>%</span> (CR/nCR, <span style='background:#ffc0cb'>37</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>5</span><span style='background:#ffc0cb'>%</span>; very good partial<br />response [VGPR] or better, <span style='background:#ffc0cb'>57</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>5</span><span style='background:#ffc0cb'>%</span>). Patients</td></tr>\n",
       "<tr><td>21189393.txt</td><td>). For<br />DLBCL, the evaluable <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> was <span style='background:#ffc0cb'>100</span><span style='background:#ffc0cb'>%</span> with <span style='background:#ffc0cb'>86</span><span style='background:#ffc0cb'>%</span> complete<br />response (CR)/CR unconfirmed (CRu; n = 35). Intent</td></tr>\n",
       "<tr><td>21189393.txt</td><td>). Intent-to-treat (ITT, n = 40) <span style='background:#90ee90'>ORR</span> was<br /><span style='background:#ffc0cb'>88</span><span style='background:#ffc0cb'>%</span> with <span style='background:#ffc0cb'>75</span><span style='background:#ffc0cb'>%</span> CR/CRu, 2-year progression-free survival (PFS) of <span style='background:#ffc0cb'>64</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI, <span style='background:#ffc0cb'>47</span><span style='background:#ffc0cb'>%</span><br />to <span style='background:#ffc0cb'>77</span><span style='background:#ffc0cb'>%</span>) and 2-year overall survival (OS) of <span style='background:#ffc0cb'>70</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI, <span style='background:#ffc0cb'>53</span><span style='background:#ffc0cb'>%</span> to <span style='background:#ffc0cb'>82</span><span style='background:#ffc0cb'>%</span>). For</td></tr>\n",
       "<tr><td>21189393.txt</td><td>). For MCL,<br />the evaluable <span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>91</span><span style='background:#ffc0cb'>%</span> with <span style='background:#ffc0cb'>72</span><span style='background:#ffc0cb'>%</span> CR/CRu (n = 32). The</td></tr>\n",
       "<tr><td>21189393.txt</td><td>). The ITT (n = 36) <span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>81</span><span style='background:#ffc0cb'>%</span> <br />with <span style='background:#ffc0cb'>64</span><span style='background:#ffc0cb'>%</span> CR/CRu, 2-year PFS <span style='background:#ffc0cb'>44</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI, <span style='background:#ffc0cb'>27</span><span style='background:#ffc0cb'>%</span> to <span style='background:#ffc0cb'>60</span><span style='background:#ffc0cb'>%</span>) and 2-year OS <span style='background:#ffc0cb'>86</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI,<br /><span style='background:#ffc0cb'>70</span><span style='background:#ffc0cb'>%</span> to <span style='background:#ffc0cb'>94</span><span style='background:#ffc0cb'>%</span>). IPI</td></tr>\n",
       "<tr><td>21315428.txt</td><td>).The <span style='background:#90ee90'>overall</span><span style='background:#90ee90'><br /></span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> was <span style='background:#ffc0cb'>63</span><span style='background:#ffc0cb'>%</span> (complete response (CR) <span style='background:#ffc0cb'>34</span><span style='background:#ffc0cb'>%</span> and partial response (PR)<br /><span style='background:#ffc0cb'>29</span><span style='background:#ffc0cb'>%</span>) for paclitaxel/bevacizumab and <span style='background:#ffc0cb'>48</span><span style='background:#ffc0cb'>%</span> (CR <span style='background:#ffc0cb'>17</span><span style='background:#ffc0cb'>%</span> and PR <span style='background:#ffc0cb'>31</span><span style='background:#ffc0cb'>%</span>) for weekly paclitaxel<br />(p=0.23). Improvement</td></tr>\n",
       "<tr><td>22078932.txt</td><td>function. The primary end-point was objective response rate (<span style='background:#90ee90'>ORR</span>) per<br />response evaluation criteria in solid tumors (RECIST) by central imaging.<br />Secondary</td></tr>\n",
       "<tr><td>22078932.txt</td><td>histology.<br /><span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>13</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>2</span><span style='background:#ffc0cb'>%</span>, median PFS was 5.4 months (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> Confidence Interval (CI): 3.6, 6.0)<br />and TTP was the same; median OS was 14.5 months (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI: 10.8, 24.1). The</td></tr>\n",
       "<tr><td>19997960.txt</td><td>patients. The objectives were to evaluate <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span>,<br />progression-free survival (PFS), overall survival (OS), and safety of cetuximab<br />plus XELOX.<br />METHODS</td></tr>\n",
       "<tr><td>19968498.txt</td><td>). Among patients treated with above doses of GPM,<br />there was 1 complete remission (CR) and 2 partial remissions (PR) with an <span style='background:#90ee90'>overall</span><span style='background:#90ee90'><br /></span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> of <span style='background:#ffc0cb'>6</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>7</span><span style='background:#ffc0cb'>%</span>. Disease</td></tr>\n",
       "<tr><td>16197624.txt</td><td>).<br />PATIENTS AND METHODS: Individual data of 254 patients were merged, and baseline<br />features potentially affecting <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span>, progression-free<br />survival (PFS), overall survival (OS), and occurrence of severe toxicity were<br />analyzed by univariate and multivariate analyses.<br />RESULTS</td></tr>\n",
       "<tr><td>16197624.txt</td><td>analyses.<br />RESULTS: In the pooled series, <span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>33</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> confidence interval [CI],<br /><span style='background:#ffc0cb'>27</span><span style='background:#ffc0cb'>%</span><span style='background:#ffc0cb'>-</span><span style='background:#ffc0cb'>39</span><span style='background:#ffc0cb'>%</span>). Liver</td></tr>\n",
       "<tr><td>16197624.txt</td><td>). Liver-only disease (<span style='background:#ffc0cb'>47</span><span style='background:#ffc0cb'>%</span> vs. <span style='background:#ffc0cb'>25</span><span style='background:#ffc0cb'>%</span>; P=0.0012) and absence of previous<br />weight loss (<span style='background:#ffc0cb'>38</span><span style='background:#ffc0cb'>%</span> vs. <span style='background:#ffc0cb'>20</span><span style='background:#ffc0cb'>%</span>; P=0.0189) were significantly associated with a higher<br /><span style='background:#90ee90'>ORR</span> on the multivariate analysis. Absence</td></tr>\n",
       "<tr><td>19386096.txt</td><td>).<br />Primary end points were objective response rate (<span style='background:#90ee90'>ORR</span>) and rate of radical (R0)<br />surgical resection. Secondary</td></tr>\n",
       "<tr><td>19386096.txt</td><td>). <span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>49</span><span style='background:#ffc0cb'>%</span> in the XELIRI and <span style='background:#ffc0cb'>48</span><span style='background:#ffc0cb'>%</span> in the<br />FOLFIRI arm (p = 0.76). The</td></tr>\n",
       "<tr><td>19386096.txt</td><td>).<br />CONCLUSION: The XELIRI regimen showed similar <span style='background:#90ee90'>ORR</span> as the FOLFIRI regimen in the<br />neoadjuvant treatment of patients with MCRC. In</td></tr>\n",
       "<tr><td>20211502.txt</td><td>1. The <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> was <span style='background:#ffc0cb'>44</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>4</span><span style='background:#ffc0cb'>%</span> and similar to<br />original study. Median</td></tr>\n",
       "<tr><td>22127285.txt</td><td>d., the objective response rate (<span style='background:#90ee90'>ORR</span>) was <span style='background:#ffc0cb'>13</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>8</span><span style='background:#ffc0cb'>%</span>, the clinical<br />benefit rate (<span style='background:#90ee90'>ORR</span>+SD) was <span style='background:#ffc0cb'>72</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>4</span><span style='background:#ffc0cb'>%</span>, the 6-month progression-free survival (PFS) was <br /><span style='background:#ffc0cb'>20</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>7</span><span style='background:#ffc0cb'>%</span>, and the 12-month overall survival (OS) was <span style='background:#ffc0cb'>34</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>5</span><span style='background:#ffc0cb'>%</span>. Two</td></tr>\n",
       "<tr><td>20466745.txt</td><td><span style='background:#ffc0cb'>%</span>. Overall response rate (<span style='background:#90ee90'>ORR</span>) was <span style='background:#ffc0cb'>43</span><span style='background:#ffc0cb'>%</span> in the total<br />cohort and <span style='background:#ffc0cb'>49</span><span style='background:#ffc0cb'>%</span> in the subgroup of 17p-deleted patients (n = 35). From</td></tr>\n",
       "<tr><td>20466745.txt</td><td>respectively. The<br />poor-risk group of patients with CLL (i.e. fludarabine resistant, 17p deletion; n<br />= 20) showed encouraging <span style='background:#90ee90'>ORR</span>, PFS, and OS (<span style='background:#ffc0cb'>35</span><span style='background:#ffc0cb'>%</span>, 7.0 and 19.2 months,<br />respectively).<br />CONCLUSIONS</td></tr>\n",
       "<tr><td>20585851.txt</td><td>cycle. The primary end point was progression free survival (PFS);<br />secondary end points were <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span>, complete (CR) and partial <br />(PR) response rates, clinical benefit (<span style='background:#90ee90'>ORR</span> + stable disease), overall survival<br />(OS), and safety. Thirty</td></tr>\n",
       "<tr><td>20585851.txt</td><td>). <span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>75</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>9</span><span style='background:#ffc0cb'>%</span>, comprising eight (<span style='background:#ffc0cb'>27</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>6</span><span style='background:#ffc0cb'>%</span>) CRs and 14 (<span style='background:#ffc0cb'>48</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>%</span>) PRs; five<br />patients had stable disease (SD) and two patients (<span style='background:#ffc0cb'>6</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>9</span><span style='background:#ffc0cb'>%</span>) had progressive disease <br />(PD) as their best response. The</td></tr>\n",
       "<tr><td>20351334.txt</td><td>). Secondary end points included<br />response rate (<span style='background:#90ee90'>ORR</span>), response duration, overall survival (OS), clinical benefit, <br />quality of life (QOL), and safety.<br />RESULTS</td></tr>\n",
       "<tr><td>20351334.txt</td><td>). <span style='background:#90ee90'>ORR</span>, stable disease, median OS, were <span style='background:#ffc0cb'>4</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>4</span><span style='background:#ffc0cb'>%</span> versus <span style='background:#ffc0cb'>5</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>5</span><span style='background:#ffc0cb'>%</span>, <span style='background:#ffc0cb'>36</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>0</span><span style='background:#ffc0cb'>%</span> versus<br /><span style='background:#ffc0cb'>39</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>6</span><span style='background:#ffc0cb'>%</span>, 6.7 versus 7.2 months (HR, 0.973; <span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI, 0.805 to 1.176), respectively.<br />No</td></tr>\n",
       "<tr><td>17099879.txt</td><td>toxicity. Secondary endpoints were the complete response<br />(CR) rate, the <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span>, and progression-free survival (PFS). <br />Weekly</td></tr>\n",
       "<tr><td>17099879.txt</td><td>reported. Thirteen of 15 patients responded (<span style='background:#90ee90'>ORR</span>,<br /><span style='background:#ffc0cb'>87</span><span style='background:#ffc0cb'>%</span>,), including 10 CRs (<span style='background:#ffc0cb'>67</span><span style='background:#ffc0cb'>%</span>), 3 partial responses (<span style='background:#ffc0cb'>20</span><span style='background:#ffc0cb'>%</span>), 1 patient with stable<br />disease, and 1 patient with disease progression. At</td></tr>\n",
       "<tr><td>21823829.txt</td><td>therapies. The primary endpoint was the objective response<br />rate (<span style='background:#90ee90'>ORR</span>), with secondary endpoints of progression-free survival (PFS), overall <br />survival (OS), safety and tolerability. A</td></tr>\n",
       "<tr><td>21823829.txt</td><td>months. The <span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>4</span><span style='background:#ffc0cb'>%</span> (one partial response). Median</td></tr>\n",
       "<tr><td>16078261.txt</td><td>).<br />RESULTS: The <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> on an intent-to-treat basis was <span style='background:#ffc0cb'>15</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span><br />confidence interval [<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI], <span style='background:#ffc0cb'>4</span><span style='background:#ffc0cb'>-</span><span style='background:#ffc0cb'>26</span><span style='background:#ffc0cb'>%</span>). A</td></tr>\n",
       "<tr><td>18669461.txt</td><td>study. The primary end point was objective<br />response rate (<span style='background:#90ee90'>ORR</span>). Secondary</td></tr>\n",
       "<tr><td>18669461.txt</td><td>enrolled. The <span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>23</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>0</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI, <span style='background:#ffc0cb'>13</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>2</span><span style='background:#ffc0cb'>%</span> to<br /><span style='background:#ffc0cb'>35</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>5</span><span style='background:#ffc0cb'>%</span>), median PFS was 30.4 weeks (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI, 18.3 to 36.7 weeks), median DR was<br />44.1 weeks (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI, 25.0 to 102.7 weeks), and median OS was 47.1 weeks (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI,<br />36.9 to 79.4 weeks). Mean</td></tr>\n",
       "<tr><td>18669461.txt</td><td>treatment. Lower<br />baseline levels of sVEGFR-3 and VEGF-C were associated with longer PFS and <span style='background:#90ee90'>ORR</span>.<br />Most</td></tr>\n",
       "<tr><td>20367963.txt</td><td>). Objective response rate (<span style='background:#90ee90'>ORR</span>) was achieved in <span style='background:#ffc0cb'>18</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>8</span><span style='background:#ffc0cb'>%</span> and clinical benefit<br />(CR + PR + SD > 6 months) in <span style='background:#ffc0cb'>68</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>8</span><span style='background:#ffc0cb'>%</span>. The</td></tr>\n",
       "<tr><td>20978503.txt</td><td>profile.<br />RESULTS: The <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> was <span style='background:#ffc0cb'>67</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>4</span><span style='background:#ffc0cb'>%</span>, with a disease control rate<br />(<span style='background:#90ee90'>ORR</span>+stable disease) of <span style='background:#ffc0cb'>93</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>5</span><span style='background:#ffc0cb'>%</span>. Median</td></tr>\n",
       "<tr><td>18936475.txt</td><td>). Secondary end points were<br />progression-free survival (PFS), objective response rate (<span style='background:#90ee90'>ORR</span>), and safety.<br />RESULTS</td></tr>\n",
       "<tr><td>18936475.txt</td><td>). Bevacizumab plus IFN had a higher <span style='background:#90ee90'>ORR</span> as compared with <br />IFN (<span style='background:#ffc0cb'>25</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>5</span><span style='background:#ffc0cb'>%</span> [<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI, <span style='background:#ffc0cb'>20</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>9</span><span style='background:#ffc0cb'>%</span> to <span style='background:#ffc0cb'>30</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>6</span><span style='background:#ffc0cb'>%</span>] v <span style='background:#ffc0cb'>13</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>1</span><span style='background:#ffc0cb'>%</span> [<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI, <span style='background:#ffc0cb'>9</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>5</span><span style='background:#ffc0cb'>%</span> to <span style='background:#ffc0cb'>17</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>%</span>]; P < .0001</td></tr>\n",
       "<tr><td>18936475.txt</td><td>).<br />CONCLUSION: Bevacizumab plus IFN produces a superior PFS and <span style='background:#90ee90'>ORR</span> in untreated<br />patients with metastatic RCC as compared with IFN monotherapy. Toxicity</td></tr>\n",
       "<tr><td>22161771.txt</td><td>]. The<br /><span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> of EGFR-TKI was <span style='background:#ffc0cb'>66</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>60</span><span style='background:#ffc0cb'>%</span>, whereas the <span style='background:#90ee90'>ORR</span> of<br />chemotherapy regimen was <span style='background:#ffc0cb'>30</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>62</span><span style='background:#ffc0cb'>%</span>, which was also a statistically significant favor<br />for EGFR-TKI [relative risk (RR)=5.68; <span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI=3.17-10.18; p<0.001]. The</td></tr>\n",
       "<tr><td>21532504.txt</td><td>cells. Studies<br />have shown that endostar plus vinorelbine-cisplatin chemotherapy could improve<br />objective response rates (<span style='background:#90ee90'>ORR</span>) and overall survival (OS) of advanced non-small<br />cell lung cancer (NSCLC) patients. This</td></tr>\n",
       "<tr><td>21532504.txt</td><td>group. <span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>39</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>%</span> in the treatment group versus <span style='background:#ffc0cb'>23</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>0</span><span style='background:#ffc0cb'>%</span> in the<br />control group (p = 0.078), and the disease control rate was <span style='background:#ffc0cb'>90</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>2</span><span style='background:#ffc0cb'>%</span> versus <span style='background:#ffc0cb'>67</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>2</span><span style='background:#ffc0cb'>%</span> (p<br />= 0.004), respectively. The</td></tr>\n",
       "<tr><td>21532504.txt</td><td>groups.<br />CONCLUSIONS: In previously untreated, advanced NSCLC patients, treatment with TC <br />plus endostar seemed to improve <span style='background:#90ee90'>ORR</span>. However</td></tr>\n",
       "<tr><td>21431341.txt</td><td>). An objective response rate (<span style='background:#90ee90'>ORR</span>) was 11 of 21 patients (<span style='background:#ffc0cb'>52</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>4</span><span style='background:#ffc0cb'>%</span>),<br />including a complete response in 1 (<span style='background:#ffc0cb'>4</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>8</span><span style='background:#ffc0cb'>%</span>). The</td></tr>\n",
       "<tr><td>21431341.txt</td><td>months. Among 16 patients who had previously received MVAC, the<br /><span style='background:#90ee90'>ORR</span>, the median PFS, the median OS and 1-year survival rate was <span style='background:#ffc0cb'>56</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>%</span>,<br />5.0 months, 12.6 months and <span style='background:#ffc0cb'>54</span><span style='background:#ffc0cb'>%</span>, respectively.<br />CONCLUSIONS</td></tr>\n",
       "<tr><td>21498742.txt</td><td>).<br />RESULTS: Overall, the objective response rate (<span style='background:#90ee90'>ORR</span>) was <span style='background:#ffc0cb'>29</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI: 20-40).<br />The</td></tr>\n",
       "<tr><td>21498742.txt</td><td>).<br />The <span style='background:#90ee90'>ORR</span> in HER2-negative/hormonal receptor (HRe) positive and<br />HER2-negative/HRe-negative patients were <span style='background:#ffc0cb'>37</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI: 26-50) and <span style='background:#ffc0cb'>0</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI:<br />0-19), respectively, (p=0.003, Fisher's test). With</td></tr>\n",
       "<tr><td>22020810.txt</td><td>. Primary endpoint <br />was the <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span>. Secondary</td></tr>\n",
       "<tr><td>22020810.txt</td><td>12. Twenty-seven valuable patients: <span style='background:#90ee90'>ORR</span> <span style='background:#ffc0cb'>30</span><span style='background:#ffc0cb'>%</span> <br />(CI0.14); disease control rate <span style='background:#ffc0cb'>85</span><span style='background:#ffc0cb'>%</span> (CI0.18). Median</td></tr>\n",
       "<tr><td>14962257.txt</td><td><span style='background:#ffc0cb'>%</span>. The <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> was <span style='background:#ffc0cb'>81</span><span style='background:#ffc0cb'>%</span><br />with a <span style='background:#ffc0cb'>57</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>6</span><span style='background:#ffc0cb'>%</span> overall survival (OS) at 62 months (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI: <span style='background:#ffc0cb'>45</span><span style='background:#ffc0cb'>-</span><span style='background:#ffc0cb'>69</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>%</span>) and a<br />progression free survival (PFS) of <span style='background:#ffc0cb'>42</span><span style='background:#ffc0cb'>%</span> at 74 months (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI: 26.<span style='background:#ffc0cb'>7</span><span style='background:#ffc0cb'>-</span><span style='background:#ffc0cb'>58</span><span style='background:#ffc0cb'>%</span>). The</td></tr>\n",
       "</table></html>"
      ]
     },
     "execution_count": 1,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "%inputDir input/pubmed_abstracts/txt100/\n",
    "%outputDir output/orr_stage1/\n",
    "%displayMode CSV\n",
    "%csvConfig SentenceWithORRInd\n",
    "\n",
    "// Detect sentence ends. Avoid interpreting a dot in a number \"5.6\" as sentence end.\n",
    "DECLARE SentEnd, Sentence;\n",
    "BLOCK(Sentence) Document{}{\n",
    "    PERIOD{-> SentEnd};\n",
    "    NUM se:SentEnd{-> UNMARK(se)} NUM;\n",
    "    se:SentEnd{-> UNMARK(se)} SW;\n",
    "    SW se:SentEnd{-> UNMARK(se)} NUM _{-PARTOF(PERIOD)};\n",
    "    ANY+{-PARTOF(Sentence),-PARTOF(SentEnd)-> Sentence};\n",
    "}\n",
    "\n",
    "// Find mentionings of overall response rate, treat brackets correctly, detect numbers\n",
    "DECLARE ORRInd, Value;\n",
    "DECLARE ORR (Annotation keyword, Value value, Sentence sentence);\n",
    "WORDLIST orrList = 'wordlists/orr_indicators.txt';\n",
    "MARKFAST(ORRInd, orrList);\n",
    "i1:ORRInd{->i1.end=p2.end, UNMARK(i2)} p1:\"(\" i2:ORRInd p2:\")\";\n",
    "(NUM{-PARTOF(Value)} (PERIOD NUM)? SPECIAL.ct==\"%\"){-> Value};\n",
    "n:NUM SPECIAL.ct==\"%\"? SPECIAL.ct==\"-\" v:@Value{-> v.begin = n.begin};\n",
    "\n",
    "// Find sentence that contain an overall response rate indicator\n",
    "DECLARE SentenceWithORRInd;\n",
    "(ANY ANY @Sentence{CONTAINS(ORRInd)} ANY ANY){-> SentenceWithORRInd};\n",
    "\n",
    "// Highlight relevant entities within the table.\n",
    "COLOR(ORRInd, \"lightgreen\");\n",
    "COLOR(Value, \"pink\");"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "numeric-profit",
   "metadata": {
    "kernel": "UIMA Ruta"
   },
   "source": [
    "## Step 2: Collecting ORR with their values in a csv table"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "clean-grenada",
   "metadata": {
    "kernel": "UIMA Ruta"
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Processed 100/100 files. (took 2s)\n",
      "78 rows created.\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<html><table>\n",
       "<tr><td>16360546.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> of <span style='background:#ffc0cb'>53</span><span style='background:#ffc0cb'>-</span><span style='background:#ffc0cb'>62</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>53</span><span style='background:#ffc0cb'>-</span><span style='background:#ffc0cb'>62</span><span style='background:#ffc0cb'>%</span></td><td>Carboplatin<br />combined with paclitaxel or docetaxel is more effective than carboplatin or<br />taxanes alone, with <span style='background:#90ee90'>ORR</span> of <span style='background:#ffc0cb'>53</span><span style='background:#ffc0cb'>-</span><span style='background:#ffc0cb'>62</span><span style='background:#ffc0cb'>%</span></td></tr>\n",
       "<tr><td>16197624.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>33</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>33</span><span style='background:#ffc0cb'>%</span></td><td>RESULTS: In the pooled series, <span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>33</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> confidence interval [CI],<br /><span style='background:#ffc0cb'>27</span><span style='background:#ffc0cb'>%</span><span style='background:#ffc0cb'>-</span><span style='background:#ffc0cb'>39</span><span style='background:#ffc0cb'>%</span>)</td></tr>\n",
       "<tr><td>18720480.txt.xmi</td><td><span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> was <span style='background:#ffc0cb'>16</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span></td><td><span style='background:#ffc0cb'>16</span><span style='background:#ffc0cb'>%</span></td><td>The <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> was <span style='background:#ffc0cb'>16</span><span style='background:#ffc0cb'>%</span><br />and included 3 complete responses that lasted 10.8 months, > or =32 months, and ><br />or =36 months and 2 partial responses that lasted 13 months and 14 months</td></tr>\n",
       "<tr><td>18815728.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>21</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>1</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>21</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>1</span><span style='background:#ffc0cb'>%</span></td><td>By intent-to-treat<br />analysis, <span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>21</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>1</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI, 8.7-43.7) and disease control rate was <span style='background:#ffc0cb'>52</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>6</span><span style='background:#ffc0cb'>%</span><br />(<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI 31.5-72.8) with four PRs and six SDs</td></tr>\n",
       "<tr><td>21823829.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>4</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>4</span><span style='background:#ffc0cb'>%</span></td><td>The <span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>4</span><span style='background:#ffc0cb'>%</span> (one partial response)</td></tr>\n",
       "<tr><td>19804901.txt.xmi</td><td><span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'><br /></span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> was <span style='background:#ffc0cb'>60</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'><br /></span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span></td><td><span style='background:#ffc0cb'>60</span><span style='background:#ffc0cb'>%</span></td><td>The <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'><br /></span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> was <span style='background:#ffc0cb'>60</span><span style='background:#ffc0cb'>%</span> (CR <span style='background:#ffc0cb'>25</span><span style='background:#ffc0cb'>%</span> and PR <span style='background:#ffc0cb'>35</span><span style='background:#ffc0cb'>%</span>)</td></tr>\n",
       "<tr><td>21561763.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>9</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>9</span><span style='background:#ffc0cb'>%</span></td><td>In<br />the intention to treat population (n=51); the <span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>9</span><span style='background:#ffc0cb'>%</span>, median PFS was 1.28<br />months [<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI, 1.18-1.90], median OS was 5.81 months [<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI, 3.48-12.32], the<br />estimated one-year survival rate was <span style='background:#ffc0cb'>23</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>7</span><span style='background:#ffc0cb'>%</span> [<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span>CI: 12.8-36.5]</td></tr>\n",
       "<tr><td>18669461.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>23</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>0</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>23</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>0</span><span style='background:#ffc0cb'>%</span></td><td>The <span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>23</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>0</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI, <span style='background:#ffc0cb'>13</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>2</span><span style='background:#ffc0cb'>%</span> to<br /><span style='background:#ffc0cb'>35</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>5</span><span style='background:#ffc0cb'>%</span>), median PFS was 30.4 weeks (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI, 18.3 to 36.7 weeks), median DR was<br />44.1 weeks (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI, 25.0 to 102.7 weeks), and median OS was 47.1 weeks (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI,<br />36.9 to 79.4 weeks)</td></tr>\n",
       "<tr><td>20581887.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>85</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>85</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>85</span><span style='background:#ffc0cb'>%</span> (CR <span style='background:#ffc0cb'>12</span><span style='background:#ffc0cb'>%</span>, very good PR <span style='background:#ffc0cb'>43</span><span style='background:#ffc0cb'>%</span> and PR <span style='background:#ffc0cb'>30</span><span style='background:#ffc0cb'>%</span>)</td></tr>\n",
       "<tr><td>21135284.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> of <span style='background:#ffc0cb'>44</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>44</span><span style='background:#ffc0cb'>%</span></td><td>CONCLUSION: Amrubicin shows promising activity, with an <span style='background:#90ee90'>ORR</span> of <span style='background:#ffc0cb'>44</span><span style='background:#ffc0cb'>%</span> compared with <br />an <span style='background:#90ee90'>ORR</span> of <span style='background:#ffc0cb'>15</span><span style='background:#ffc0cb'>%</span> for topotecan as second-line treatment in patients with SCLC<br />sensitive to first-line platinum-based chemotherapy</td></tr>\n",
       "<tr><td>21135284.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> of <span style='background:#ffc0cb'>15</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>15</span><span style='background:#ffc0cb'>%</span></td><td>CONCLUSION: Amrubicin shows promising activity, with an <span style='background:#90ee90'>ORR</span> of <span style='background:#ffc0cb'>44</span><span style='background:#ffc0cb'>%</span> compared with <br />an <span style='background:#90ee90'>ORR</span> of <span style='background:#ffc0cb'>15</span><span style='background:#ffc0cb'>%</span> for topotecan as second-line treatment in patients with SCLC<br />sensitive to first-line platinum-based chemotherapy</td></tr>\n",
       "<tr><td>21728023.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> of <span style='background:#ffc0cb'>25</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>25</span><span style='background:#ffc0cb'>%</span></td><td>Two complete responses and 12 partial responses were<br />observed for an <span style='background:#90ee90'>ORR</span> of <span style='background:#ffc0cb'>25</span><span style='background:#ffc0cb'>%</span></td></tr>\n",
       "<tr><td>19862815.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>30</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>30</span><span style='background:#ffc0cb'>%</span></td><td>The <span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>30</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> confidence interval [CI],<br /><span style='background:#ffc0cb'>16</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>6</span><span style='background:#ffc0cb'>%</span><span style='background:#ffc0cb'>-</span><span style='background:#ffc0cb'>46</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>5</span><span style='background:#ffc0cb'>%</span>) in the sorafenib arm and <span style='background:#ffc0cb'>25</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI, <span style='background:#ffc0cb'>12</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>7</span><span style='background:#ffc0cb'>%</span><span style='background:#ffc0cb'>-</span><span style='background:#ffc0cb'>41</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>2</span><span style='background:#ffc0cb'>%</span>) in the<br />combination arm</td></tr>\n",
       "<tr><td>20212251.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> reached <span style='background:#ffc0cb'>47</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>47</span><span style='background:#ffc0cb'>%</span></td><td>The CR and <span style='background:#90ee90'>ORR</span> reached <span style='background:#ffc0cb'>47</span><span style='background:#ffc0cb'>%</span> and <span style='background:#ffc0cb'>88</span><span style='background:#ffc0cb'>%</span> in the CC arm and <span style='background:#ffc0cb'>46</span><span style='background:#ffc0cb'>%</span> and <span style='background:#ffc0cb'>82</span><span style='background:#ffc0cb'>%</span> in the<br />FC arm (P =</td></tr>\n",
       "<tr><td>22000696.txt.xmi</td><td><span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> was<br /><span style='background:#ffc0cb'>24</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>5</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span></td><td><span style='background:#ffc0cb'>24</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>5</span><span style='background:#ffc0cb'>%</span></td><td>RESULTS: In an intention-to-treat analysis, the <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> was<br /><span style='background:#ffc0cb'>24</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>5</span><span style='background:#ffc0cb'>%</span></td></tr>\n",
       "<tr><td>22000696.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>66</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>7</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>66</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>7</span><span style='background:#ffc0cb'>%</span></td><td>The <span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>66</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>7</span><span style='background:#ffc0cb'>%</span> in patients with activating EGFR<br />mutations and <span style='background:#ffc0cb'>14</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>8</span><span style='background:#ffc0cb'>%</span> in patients with wild-type EGFR (2P =</td></tr>\n",
       "<tr><td>22017239.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>6</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>6</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>6</span><span style='background:#ffc0cb'>%</span>, median PFS was 2.2 months, and OS 4.3 months</td></tr>\n",
       "<tr><td>19628292.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>31</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>7</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>31</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>7</span><span style='background:#ffc0cb'>%</span></td><td>Efficacy was assessed in<br />patients who completed at least 1 cycle of treatment; <span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>31</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>7</span><span style='background:#ffc0cb'>%</span> in arm A<br />versus <span style='background:#ffc0cb'>25</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>6</span><span style='background:#ffc0cb'>%</span> in arm B and DCR was <span style='background:#ffc0cb'>70</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>7</span><span style='background:#ffc0cb'>%</span> versus <span style='background:#ffc0cb'>56</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>4</span><span style='background:#ffc0cb'>%</span>, respectively</td></tr>\n",
       "<tr><td>21532504.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>39</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>39</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>39</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>%</span> in the treatment group versus <span style='background:#ffc0cb'>23</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>0</span><span style='background:#ffc0cb'>%</span> in the<br />control group (p = 0.078), and the disease control rate was <span style='background:#ffc0cb'>90</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>2</span><span style='background:#ffc0cb'>%</span> versus <span style='background:#ffc0cb'>67</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>2</span><span style='background:#ffc0cb'>%</span> (p<br />= 0.004), respectively</td></tr>\n",
       "<tr><td>22078932.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>13</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>2</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>13</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>2</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>13</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>2</span><span style='background:#ffc0cb'>%</span>, median PFS was 5.4 months (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> Confidence Interval (CI): 3.6, 6.0)<br />and TTP was the same; median OS was 14.5 months (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI: 10.8, 24.1)</td></tr>\n",
       "<tr><td>21479652.txt.xmi</td><td><span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> of<br /><span style='background:#ffc0cb'>65</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span></td><td><span style='background:#ffc0cb'>65</span><span style='background:#ffc0cb'>%</span></td><td>In CLL, an <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> of<br /><span style='background:#ffc0cb'>65</span><span style='background:#ffc0cb'>%</span> was achieved</td></tr>\n",
       "<tr><td>21479652.txt.xmi</td><td><span style='background:#90ee90'>ORR</span><br />was <span style='background:#ffc0cb'>86</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>86</span><span style='background:#ffc0cb'>%</span></td><td>Notably, in the seven previously untreated CLL patients, <span style='background:#90ee90'>ORR</span><br />was <span style='background:#ffc0cb'>86</span><span style='background:#ffc0cb'>%</span></td></tr>\n",
       "<tr><td>21479652.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> <span style='background:#ffc0cb'>96</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>96</span><span style='background:#ffc0cb'>%</span></td><td>In indolent lymphoma (n = 25), the bendamustine-rituximab<br />combination induced a remarkable therapeutic effect (<span style='background:#90ee90'>ORR</span> <span style='background:#ffc0cb'>96</span><span style='background:#ffc0cb'>%</span>, median PFS and OS<br />not reached)</td></tr>\n",
       "<tr><td>21479652.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>50</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>50</span><span style='background:#ffc0cb'>%</span></td><td>In aggressive lymphoma (n = 20), <span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>50</span><span style='background:#ffc0cb'>%</span>; in International<br />Prognostic Index high-risk patients (4 or 5 risk factors, n = 10), <span style='background:#90ee90'>ORR</span> was only<br /><span style='background:#ffc0cb'>20</span><span style='background:#ffc0cb'>%</span>, significantly inferior than in low/intermediate risk patients (<span style='background:#90ee90'>ORR</span> <span style='background:#ffc0cb'>70</span><span style='background:#ffc0cb'>%</span>; p = <br />0.025)</td></tr>\n",
       "<tr><td>21479652.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> <span style='background:#ffc0cb'>70</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>70</span><span style='background:#ffc0cb'>%</span></td><td>In aggressive lymphoma (n = 20), <span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>50</span><span style='background:#ffc0cb'>%</span>; in International<br />Prognostic Index high-risk patients (4 or 5 risk factors, n = 10), <span style='background:#90ee90'>ORR</span> was only<br /><span style='background:#ffc0cb'>20</span><span style='background:#ffc0cb'>%</span>, significantly inferior than in low/intermediate risk patients (<span style='background:#90ee90'>ORR</span> <span style='background:#ffc0cb'>70</span><span style='background:#ffc0cb'>%</span>; p = <br />0.025)</td></tr>\n",
       "<tr><td>21472713.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> of <span style='background:#ffc0cb'>22</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>22</span><span style='background:#ffc0cb'>%</span></td><td>Patients with platinum-resistant disease achieved an <span style='background:#90ee90'>ORR</span> of <span style='background:#ffc0cb'>22</span><span style='background:#ffc0cb'>%</span>, with a median<br />PFS of 5.6 months and a median OS of 23 months</td></tr>\n",
       "<tr><td>19652060.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>22</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>6</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>22</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>6</span><span style='background:#ffc0cb'>%</span></td><td>In 62 patients<br />evaluable for response, the <span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>22</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>6</span><span style='background:#ffc0cb'>%</span>, and the median duration of response<br />was 17.5 months</td></tr>\n",
       "<tr><td>19687333.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> of <span style='background:#ffc0cb'>5</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>4</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>5</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>4</span><span style='background:#ffc0cb'>%</span></td><td>Two patients achieved a confirmed <br />partial response, with an <span style='background:#90ee90'>ORR</span> of <span style='background:#ffc0cb'>5</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>4</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI, <span style='background:#ffc0cb'>0</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>7</span><span style='background:#ffc0cb'>%</span> to <span style='background:#ffc0cb'>18</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>2</span><span style='background:#ffc0cb'>%</span>)</td></tr>\n",
       "<tr><td>21189393.txt.xmi</td><td><span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> was <span style='background:#ffc0cb'>100</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span></td><td><span style='background:#ffc0cb'>100</span><span style='background:#ffc0cb'>%</span></td><td>For<br />DLBCL, the evaluable <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> was <span style='background:#ffc0cb'>100</span><span style='background:#ffc0cb'>%</span> with <span style='background:#ffc0cb'>86</span><span style='background:#ffc0cb'>%</span> complete<br />response (CR)/CR unconfirmed (CRu; n = 35)</td></tr>\n",
       "<tr><td>21189393.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> was<br /><span style='background:#ffc0cb'>88</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>88</span><span style='background:#ffc0cb'>%</span></td><td>Intent-to-treat (ITT, n = 40) <span style='background:#90ee90'>ORR</span> was<br /><span style='background:#ffc0cb'>88</span><span style='background:#ffc0cb'>%</span> with <span style='background:#ffc0cb'>75</span><span style='background:#ffc0cb'>%</span> CR/CRu, 2-year progression-free survival (PFS) of <span style='background:#ffc0cb'>64</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI, <span style='background:#ffc0cb'>47</span><span style='background:#ffc0cb'>%</span><br />to <span style='background:#ffc0cb'>77</span><span style='background:#ffc0cb'>%</span>) and 2-year overall survival (OS) of <span style='background:#ffc0cb'>70</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI, <span style='background:#ffc0cb'>53</span><span style='background:#ffc0cb'>%</span> to <span style='background:#ffc0cb'>82</span><span style='background:#ffc0cb'>%</span>)</td></tr>\n",
       "<tr><td>21189393.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>91</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>91</span><span style='background:#ffc0cb'>%</span></td><td>For MCL,<br />the evaluable <span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>91</span><span style='background:#ffc0cb'>%</span> with <span style='background:#ffc0cb'>72</span><span style='background:#ffc0cb'>%</span> CR/CRu (n = 32)</td></tr>\n",
       "<tr><td>21189393.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>81</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>81</span><span style='background:#ffc0cb'>%</span></td><td>The ITT (n = 36) <span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>81</span><span style='background:#ffc0cb'>%</span> <br />with <span style='background:#ffc0cb'>64</span><span style='background:#ffc0cb'>%</span> CR/CRu, 2-year PFS <span style='background:#ffc0cb'>44</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI, <span style='background:#ffc0cb'>27</span><span style='background:#ffc0cb'>%</span> to <span style='background:#ffc0cb'>60</span><span style='background:#ffc0cb'>%</span>) and 2-year OS <span style='background:#ffc0cb'>86</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI,<br /><span style='background:#ffc0cb'>70</span><span style='background:#ffc0cb'>%</span> to <span style='background:#ffc0cb'>94</span><span style='background:#ffc0cb'>%</span>)</td></tr>\n",
       "<tr><td>21315428.txt.xmi</td><td><span style='background:#90ee90'>overall</span><span style='background:#90ee90'><br /></span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> was <span style='background:#ffc0cb'>63</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>overall</span><span style='background:#90ee90'><br /></span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span></td><td><span style='background:#ffc0cb'>63</span><span style='background:#ffc0cb'>%</span></td><td>The <span style='background:#90ee90'>overall</span><span style='background:#90ee90'><br /></span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> was <span style='background:#ffc0cb'>63</span><span style='background:#ffc0cb'>%</span> (complete response (CR) <span style='background:#ffc0cb'>34</span><span style='background:#ffc0cb'>%</span> and partial response (PR)<br /><span style='background:#ffc0cb'>29</span><span style='background:#ffc0cb'>%</span>) for paclitaxel/bevacizumab and <span style='background:#ffc0cb'>48</span><span style='background:#ffc0cb'>%</span> (CR <span style='background:#ffc0cb'>17</span><span style='background:#ffc0cb'>%</span> and PR <span style='background:#ffc0cb'>31</span><span style='background:#ffc0cb'>%</span>) for weekly paclitaxel<br />(p=0.23)</td></tr>\n",
       "<tr><td>19386096.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>49</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>49</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>49</span><span style='background:#ffc0cb'>%</span> in the XELIRI and <span style='background:#ffc0cb'>48</span><span style='background:#ffc0cb'>%</span> in the<br />FOLFIRI arm (p = 0.76)</td></tr>\n",
       "<tr><td>20066161.txt.xmi</td><td><span style='background:#90ee90'>overall</span><span style='background:#90ee90'><br /></span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> was <span style='background:#ffc0cb'>18</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>overall</span><span style='background:#90ee90'><br /></span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span></td><td><span style='background:#ffc0cb'>18</span><span style='background:#ffc0cb'>%</span></td><td>The <span style='background:#90ee90'>overall</span><span style='background:#90ee90'><br /></span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> was <span style='background:#ffc0cb'>18</span><span style='background:#ffc0cb'>%</span>; and the median progression-free (PFS) and overall<br />survival (OS) were 3.8 and 9.7 months respectively</td></tr>\n",
       "<tr><td>19287023.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> of <span style='background:#ffc0cb'>13</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>5</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>13</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>5</span><span style='background:#ffc0cb'>%</span></td><td>Seven<br />patients had partial responses for a confirmed <span style='background:#90ee90'>ORR</span> of <span style='background:#ffc0cb'>13</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>5</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI: 5.6, 25.8)</td></tr>\n",
       "<tr><td>21300933.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>46</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>46</span><span style='background:#ffc0cb'>%</span></td><td>RESULTS: In the intention-to-treat patient population (n = 177), <span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>46</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span><br />CI, 35 to 57) for CAPIRI plus cetuximab versus <span style='background:#ffc0cb'>48</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI, 37 to 59) for CAPOX<br />plus cetuximab</td></tr>\n",
       "<tr><td>21300933.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> of <span style='background:#ffc0cb'>50</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>0</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>50</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>0</span><span style='background:#ffc0cb'>%</span></td><td>Patients with KRAS wild-type in the CAPIRI <br />plus cetuximab arm showed an <span style='background:#90ee90'>ORR</span> of <span style='background:#ffc0cb'>50</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>0</span><span style='background:#ffc0cb'>%</span>, a PFS of 6.2 months and an OS of 21.1 <br />months</td></tr>\n",
       "<tr><td>21300933.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> of <span style='background:#ffc0cb'>44</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>9</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>44</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>9</span><span style='background:#ffc0cb'>%</span></td><td>In the CAPOX plus cetuximab arm, an <span style='background:#90ee90'>ORR</span> of <span style='background:#ffc0cb'>44</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>9</span><span style='background:#ffc0cb'>%</span>, a PFS of 7.1 months and<br />an OS of 23.5 months were observed</td></tr>\n",
       "<tr><td>20585851.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>75</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>9</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>75</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>9</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>75</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>9</span><span style='background:#ffc0cb'>%</span>, comprising eight (<span style='background:#ffc0cb'>27</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>6</span><span style='background:#ffc0cb'>%</span>) CRs and 14 (<span style='background:#ffc0cb'>48</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>%</span>) PRs; five<br />patients had stable disease (SD) and two patients (<span style='background:#ffc0cb'>6</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>9</span><span style='background:#ffc0cb'>%</span>) had progressive disease <br />(PD) as their best response</td></tr>\n",
       "<tr><td>20585851.txt.xmi</td><td><span style='background:#ffc0cb'>75</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>9</span><span style='background:#ffc0cb'>%</span> <span style='background:#90ee90'>ORR</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>75</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>9</span><span style='background:#ffc0cb'>%</span></td><td>First-line therapy with<br />nab-P, B, and G demonstrated a median PFS of 10.4 months and a <span style='background:#ffc0cb'>75</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>9</span><span style='background:#ffc0cb'>%</span> <span style='background:#90ee90'>ORR</span> with<br />acceptable toxicity; this novel combination warrants investigation in a<br />randomized study</td></tr>\n",
       "<tr><td>20211502.txt.xmi</td><td><span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> was <span style='background:#ffc0cb'>44</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>4</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span></td><td><span style='background:#ffc0cb'>44</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>4</span><span style='background:#ffc0cb'>%</span></td><td>The <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> was <span style='background:#ffc0cb'>44</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>4</span><span style='background:#ffc0cb'>%</span> and similar to<br />original study</td></tr>\n",
       "<tr><td>21298496.txt.xmi</td><td><span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> <br />of <span style='background:#ffc0cb'>18</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span></td><td><span style='background:#ffc0cb'>18</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>%</span></td><td>Based on an<br />intention-to-treat analysis, 60 patients were assessable for responses and 11<br />patients achieved a partial response (PR), giving an <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> <br />of <span style='background:#ffc0cb'>18</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>%</span></td></tr>\n",
       "<tr><td>19826424.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> <span style='background:#ffc0cb'>2</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>1</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>2</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>1</span><span style='background:#ffc0cb'>%</span></td><td>RESULTS: Of 47 patients receiving sunitinib, one patient achieved a confirmed<br />partial response (<span style='background:#90ee90'>ORR</span> <span style='background:#ffc0cb'>2</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>1</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> confidence interval (CI) 0.1, 11.3)) and 11<br />(<span style='background:#ffc0cb'>23</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>4</span><span style='background:#ffc0cb'>%</span>) had stable disease (SD) > or =8 weeks</td></tr>\n",
       "<tr><td>20564642.txt.xmi</td><td><span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'><br /></span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> was <span style='background:#ffc0cb'>91</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'><br /></span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span></td><td><span style='background:#ffc0cb'>91</span><span style='background:#ffc0cb'>%</span></td><td>The <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'><br /></span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> was <span style='background:#ffc0cb'>91</span><span style='background:#ffc0cb'>%</span>, which included a greater than or equal to very good partial<br />response (> or = VGPR) rate of <span style='background:#ffc0cb'>57</span><span style='background:#ffc0cb'>%</span> (including <span style='background:#ffc0cb'>20</span><span style='background:#ffc0cb'>%</span> stringent complete<br />responses/complete response [sCR/CR] rate)</td></tr>\n",
       "<tr><td>20564642.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> was<br /><span style='background:#ffc0cb'>94</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>94</span><span style='background:#ffc0cb'>%</span></td><td>In front-line patients, the <span style='background:#90ee90'>ORR</span> was<br /><span style='background:#ffc0cb'>94</span><span style='background:#ffc0cb'>%</span>, which included a <span style='background:#ffc0cb'>56</span><span style='background:#ffc0cb'>%</span> > or = VGPR rate (<span style='background:#ffc0cb'>24</span><span style='background:#ffc0cb'>%</span> sCR/CR)</td></tr>\n",
       "<tr><td>21399997.txt.xmi</td><td><span style='background:#90ee90'>ORR</span><br />was <span style='background:#ffc0cb'>62</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>5</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>62</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>5</span><span style='background:#ffc0cb'>%</span></td><td>Of the 40 evaluable female patients, the <span style='background:#90ee90'>ORR</span><br />was <span style='background:#ffc0cb'>62</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>5</span><span style='background:#ffc0cb'>%</span></td></tr>\n",
       "<tr><td>19968498.txt.xmi</td><td><span style='background:#90ee90'>overall</span><span style='background:#90ee90'><br /></span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> of <span style='background:#ffc0cb'>6</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>7</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>overall</span><span style='background:#90ee90'><br /></span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span></td><td><span style='background:#ffc0cb'>6</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>7</span><span style='background:#ffc0cb'>%</span></td><td>Among patients treated with above doses of GPM,<br />there was 1 complete remission (CR) and 2 partial remissions (PR) with an <span style='background:#90ee90'>overall</span><span style='background:#90ee90'><br /></span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> of <span style='background:#ffc0cb'>6</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>7</span><span style='background:#ffc0cb'>%</span></td></tr>\n",
       "<tr><td>11956647.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> <span style='background:#ffc0cb'>50</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>50</span><span style='background:#ffc0cb'>%</span></td><td>After 6 weeks, 30 patients were assessable for response: no CR was observed, a PR<br />was achieved in 15 patients (<span style='background:#ffc0cb'>50</span><span style='background:#ffc0cb'>%</span>; <span style='background:#90ee90'>ORR</span> <span style='background:#ffc0cb'>50</span><span style='background:#ffc0cb'>%</span>)</td></tr>\n",
       "<tr><td>11956647.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> <span style='background:#ffc0cb'>30</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>0</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>30</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>0</span><span style='background:#ffc0cb'>%</span></td><td>After 15 weeks, 1 CR and 8 PR were<br />observed (<span style='background:#90ee90'>ORR</span> <span style='background:#ffc0cb'>30</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>0</span><span style='background:#ffc0cb'>%</span>)</td></tr>\n",
       "<tr><td>11956647.txt.xmi</td><td><span style='background:#ffc0cb'>30</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>0</span><span style='background:#ffc0cb'>%</span> <span style='background:#90ee90'>ORR</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>30</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>0</span><span style='background:#ffc0cb'>%</span></td><td>The <span style='background:#ffc0cb'>30</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>0</span><span style='background:#ffc0cb'>%</span> <span style='background:#90ee90'>ORR</span>, the 15 month OS and the 10 month PFS obtained in this<br />study are comparable with those observed with cisplatin plus epirubicin (<span style='background:#90ee90'>ORR</span><br /><span style='background:#ffc0cb'>39</span><span style='background:#ffc0cb'>-</span><span style='background:#ffc0cb'>54</span><span style='background:#ffc0cb'>%</span>) in phase II studies and in a previous phase III study (<span style='background:#90ee90'>ORR</span> <span style='background:#ffc0cb'>33</span><span style='background:#ffc0cb'>%</span>, OS 10.5<br />months)</td></tr>\n",
       "<tr><td>11956647.txt.xmi</td><td><span style='background:#90ee90'>ORR</span><br /><span style='background:#ffc0cb'>39</span><span style='background:#ffc0cb'>-</span><span style='background:#ffc0cb'>54</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>39</span><span style='background:#ffc0cb'>-</span><span style='background:#ffc0cb'>54</span><span style='background:#ffc0cb'>%</span></td><td>The <span style='background:#ffc0cb'>30</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>0</span><span style='background:#ffc0cb'>%</span> <span style='background:#90ee90'>ORR</span>, the 15 month OS and the 10 month PFS obtained in this<br />study are comparable with those observed with cisplatin plus epirubicin (<span style='background:#90ee90'>ORR</span><br /><span style='background:#ffc0cb'>39</span><span style='background:#ffc0cb'>-</span><span style='background:#ffc0cb'>54</span><span style='background:#ffc0cb'>%</span>) in phase II studies and in a previous phase III study (<span style='background:#90ee90'>ORR</span> <span style='background:#ffc0cb'>33</span><span style='background:#ffc0cb'>%</span>, OS 10.5<br />months)</td></tr>\n",
       "<tr><td>11956647.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> <span style='background:#ffc0cb'>33</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>33</span><span style='background:#ffc0cb'>%</span></td><td>The <span style='background:#ffc0cb'>30</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>0</span><span style='background:#ffc0cb'>%</span> <span style='background:#90ee90'>ORR</span>, the 15 month OS and the 10 month PFS obtained in this<br />study are comparable with those observed with cisplatin plus epirubicin (<span style='background:#90ee90'>ORR</span><br /><span style='background:#ffc0cb'>39</span><span style='background:#ffc0cb'>-</span><span style='background:#ffc0cb'>54</span><span style='background:#ffc0cb'>%</span>) in phase II studies and in a previous phase III study (<span style='background:#90ee90'>ORR</span> <span style='background:#ffc0cb'>33</span><span style='background:#ffc0cb'>%</span>, OS 10.5<br />months)</td></tr>\n",
       "<tr><td>14962257.txt.xmi</td><td><span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> was <span style='background:#ffc0cb'>81</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span></td><td><span style='background:#ffc0cb'>81</span><span style='background:#ffc0cb'>%</span></td><td>The <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> was <span style='background:#ffc0cb'>81</span><span style='background:#ffc0cb'>%</span><br />with a <span style='background:#ffc0cb'>57</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>6</span><span style='background:#ffc0cb'>%</span> overall survival (OS) at 62 months (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI: <span style='background:#ffc0cb'>45</span><span style='background:#ffc0cb'>-</span><span style='background:#ffc0cb'>69</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>%</span>) and a<br />progression free survival (PFS) of <span style='background:#ffc0cb'>42</span><span style='background:#ffc0cb'>%</span> at 74 months (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI: 26.<span style='background:#ffc0cb'>7</span><span style='background:#ffc0cb'>-</span><span style='background:#ffc0cb'>58</span><span style='background:#ffc0cb'>%</span>)</td></tr>\n",
       "<tr><td>21188632.txt.xmi</td><td><span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> was <span style='background:#ffc0cb'>26</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span></td><td><span style='background:#ffc0cb'>26</span><span style='background:#ffc0cb'>%</span></td><td>Based on 35<br />evaluable patients, the <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> was <span style='background:#ffc0cb'>26</span><span style='background:#ffc0cb'>%</span> (1 CR and 8 PR), and <br />the clinical benefit rate (CR+ PR+ stable disease [SD] = 6 months) was <span style='background:#ffc0cb'>40</span><span style='background:#ffc0cb'>%</span></td></tr>\n",
       "<tr><td>20430469.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>53</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>53</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>%</span></td><td>The <span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>53</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI, 38.6-67.9) and disease control rate (DCR) including<br />stable disease was <span style='background:#ffc0cb'>86</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>7</span><span style='background:#ffc0cb'>%</span></td></tr>\n",
       "<tr><td>19451710.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> of <span style='background:#ffc0cb'>41</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>7</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>41</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>7</span><span style='background:#ffc0cb'>%</span></td><td>One complete response (<span style='background:#ffc0cb'>2</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>1</span><span style='background:#ffc0cb'>%</span>) and 19 partial responses (<span style='background:#ffc0cb'>39</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>6</span><span style='background:#ffc0cb'>%</span>) were<br />noted, resulting in an <span style='background:#90ee90'>ORR</span> of <span style='background:#ffc0cb'>41</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>7</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> confidence interval, CI: 27.<span style='background:#ffc0cb'>7</span><span style='background:#ffc0cb'>-</span><span style='background:#ffc0cb'>55</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>6</span><span style='background:#ffc0cb'>%</span>) by <br />intent-to-treat analysis</td></tr>\n",
       "<tr><td>20973869.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> of<br /><span style='background:#ffc0cb'>22</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>22</span><span style='background:#ffc0cb'>%</span></td><td>Complete response (CR) was observed<br />in four patients (<span style='background:#ffc0cb'>8</span><span style='background:#ffc0cb'>%</span>) and partial response in seven (<span style='background:#ffc0cb'>14</span><span style='background:#ffc0cb'>%</span>), yielding an <span style='background:#90ee90'>ORR</span> of<br /><span style='background:#ffc0cb'>22</span><span style='background:#ffc0cb'>%</span></td></tr>\n",
       "<tr><td>20973869.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> were <span style='background:#ffc0cb'>17</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>17</span><span style='background:#ffc0cb'>%</span></td><td>The <span style='background:#90ee90'>ORR</span> were <span style='background:#ffc0cb'>17</span><span style='background:#ffc0cb'>%</span> in the favorable- or intermediate-risk group<br />and <span style='background:#ffc0cb'>40</span><span style='background:#ffc0cb'>%</span> in the poor-risk group</td></tr>\n",
       "<tr><td>21803002.txt.xmi</td><td><span style='background:#90ee90'>ORR</span><br />was <span style='background:#ffc0cb'>32</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>32</span><span style='background:#ffc0cb'>%</span></td><td>The DCR was <span style='background:#ffc0cb'>87</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI, <span style='background:#ffc0cb'>77</span><span style='background:#ffc0cb'>%</span><span style='background:#ffc0cb'>-</span><span style='background:#ffc0cb'>97</span><span style='background:#ffc0cb'>%</span>); <span style='background:#90ee90'>ORR</span><br />was <span style='background:#ffc0cb'>32</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI, <span style='background:#ffc0cb'>19</span><span style='background:#ffc0cb'>%</span><span style='background:#ffc0cb'>-</span><span style='background:#ffc0cb'>46</span><span style='background:#ffc0cb'>%</span>)</td></tr>\n",
       "<tr><td>21709202.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>25</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>25</span><span style='background:#ffc0cb'>%</span></td><td>727), while <span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>25</span><span style='background:#ffc0cb'>%</span> in both arms (P =<br />1.0)</td></tr>\n",
       "<tr><td>22020810.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> <span style='background:#ffc0cb'>30</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>30</span><span style='background:#ffc0cb'>%</span></td><td>Twenty-seven valuable patients: <span style='background:#90ee90'>ORR</span> <span style='background:#ffc0cb'>30</span><span style='background:#ffc0cb'>%</span> <br />(CI0.14); disease control rate <span style='background:#ffc0cb'>85</span><span style='background:#ffc0cb'>%</span> (CI0.18)</td></tr>\n",
       "<tr><td>19887304.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> was <br /><span style='background:#ffc0cb'>28</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>28</span><span style='background:#ffc0cb'>%</span></td><td>The <span style='background:#90ee90'>ORR</span> was <br /><span style='background:#ffc0cb'>28</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>41</span><span style='background:#ffc0cb'>%</span> and <span style='background:#ffc0cb'>19</span><span style='background:#ffc0cb'>%</span> in patients with TFI >or=6, or <6 months, respectively); rate of<br />disease stabilization was <span style='background:#ffc0cb'>26</span><span style='background:#ffc0cb'>%</span>; response duration and median OS were 6 (2.4-26)<br />and 14 (1-46) months, respectively</td></tr>\n",
       "<tr><td>19652072.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>20</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>20</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>20</span><span style='background:#ffc0cb'>%</span> with a 7.2-month median response duration</td></tr>\n",
       "<tr><td>21908069.txt.xmi</td><td><span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> of <span style='background:#ffc0cb'>43</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span></td><td><span style='background:#ffc0cb'>43</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>%</span></td><td>Partial response was seen in 29/67 patients corresponding<br />to an <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> of <span style='background:#ffc0cb'>43</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span>CI, 28.5-53.7)</td></tr>\n",
       "<tr><td>22044606.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> of <span style='background:#ffc0cb'>32</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>8</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>32</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>8</span><span style='background:#ffc0cb'>%</span></td><td>Of the 61 patients evaluable for<br />response, there were 20 responders (one complete response and 19 partial<br />responses), for an <span style='background:#90ee90'>ORR</span> of <span style='background:#ffc0cb'>32</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>8</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI: <span style='background:#ffc0cb'>21</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>%</span>, <span style='background:#ffc0cb'>46</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>0</span><span style='background:#ffc0cb'>%</span>)</td></tr>\n",
       "<tr><td>16844257.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> of <span style='background:#ffc0cb'>37</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>37</span><span style='background:#ffc0cb'>%</span></td><td>In 27 evaluable patients with follow-up, there were 10 partial <br />responses for an <span style='background:#90ee90'>ORR</span> of <span style='background:#ffc0cb'>37</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>90</span><span style='background:#ffc0cb'>%</span> confidence interval [CI], <span style='background:#ffc0cb'>22</span><span style='background:#ffc0cb'>-</span><span style='background:#ffc0cb'>55</span><span style='background:#ffc0cb'>%</span>)</td></tr>\n",
       "<tr><td>17963264.txt.xmi</td><td><span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> was <span style='background:#ffc0cb'>59</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>4</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span></td><td><span style='background:#ffc0cb'>59</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>4</span><span style='background:#ffc0cb'>%</span></td><td>The <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> was <span style='background:#ffc0cb'>59</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>4</span><span style='background:#ffc0cb'>%</span>, comparable to younger<br />patients (<span style='background:#ffc0cb'>59</span><span style='background:#ffc0cb'>%</span>)</td></tr>\n",
       "<tr><td>21585693.txt.xmi</td><td><span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> was <span style='background:#ffc0cb'>29</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span></td><td><span style='background:#ffc0cb'>29</span><span style='background:#ffc0cb'>%</span></td><td>The <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> was <span style='background:#ffc0cb'>29</span><span style='background:#ffc0cb'>%</span>; <span style='background:#ffc0cb'>46</span><span style='background:#ffc0cb'>%</span> (three<br />complete responses, two partial responses (PR) for patients with low grade B-cell<br />NHL (LGL) and <span style='background:#ffc0cb'>9</span><span style='background:#ffc0cb'>%</span> (one PR) for patients with diffuse large B-cell lymphoma<br />(DLBCL)</td></tr>\n",
       "<tr><td>20385980.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>21</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>21</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>%</span></td><td>The <span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>21</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI, <span style='background:#ffc0cb'>12</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>7</span><span style='background:#ffc0cb'>%</span><br />to <span style='background:#ffc0cb'>32</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>%</span>), with one complete response (<span style='background:#ffc0cb'>1</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>%</span>) and 15 partial responses (<span style='background:#ffc0cb'>20</span><span style='background:#ffc0cb'>%</span>)</td></tr>\n",
       "<tr><td>20385980.txt.xmi</td><td><span style='background:#ffc0cb'>21</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>%</span> <span style='background:#90ee90'>ORR</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>21</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>%</span></td><td>CONCLUSION: Single-agent amrubicin showed promising activity with a <span style='background:#ffc0cb'>21</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>%</span> <span style='background:#90ee90'>ORR</span> and<br />an acceptable safety profile when used as second-line therapy patients with<br />platinum-refractory SCLC</td></tr>\n",
       "<tr><td>20978503.txt.xmi</td><td><span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> was <span style='background:#ffc0cb'>67</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>4</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span></td><td><span style='background:#ffc0cb'>67</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>4</span><span style='background:#ffc0cb'>%</span></td><td>RESULTS: The <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> was <span style='background:#ffc0cb'>67</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>4</span><span style='background:#ffc0cb'>%</span>, with a disease control rate<br />(<span style='background:#90ee90'>ORR</span>+stable disease) of <span style='background:#ffc0cb'>93</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>5</span><span style='background:#ffc0cb'>%</span></td></tr>\n",
       "<tr><td>21070370.txt.xmi</td><td><span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> was<br /><span style='background:#ffc0cb'>90</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span></td><td><span style='background:#ffc0cb'>90</span><span style='background:#ffc0cb'>%</span></td><td>The <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> was<br /><span style='background:#ffc0cb'>90</span><span style='background:#ffc0cb'>%</span>, with a complete response rate (CRR) of <span style='background:#ffc0cb'>70</span><span style='background:#ffc0cb'>%</span></td></tr>\n",
       "<tr><td>20593498.txt.xmi</td><td><span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> <span style='background:#ffc0cb'>43</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span></td><td><span style='background:#ffc0cb'>43</span><span style='background:#ffc0cb'>%</span></td><td>RESULTS: No significant difference was found between treatment arms A and B in<br />the progression-free survival (PFS) rate at 9 mo, <span style='background:#ffc0cb'>45</span><span style='background:#ffc0cb'>%</span> vs <span style='background:#ffc0cb'>34</span><span style='background:#ffc0cb'>%</span>; median PFS, 8.6 mo <br />vs 8.3 mo [hazard ratio (HR) = 1.06]; <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>ORR</span><span style='background:#90ee90'>)</span> <span style='background:#ffc0cb'>43</span><span style='background:#ffc0cb'>%</span> vs <span style='background:#ffc0cb'>45</span><span style='background:#ffc0cb'>%</span><br />[odds ratio (OR) = 0.93] and median overall survival (OS), 17.4 mo vs 18.9 mo (HR<br />= 0.98)</td></tr>\n",
       "<tr><td>19738129.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>85</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>0</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>85</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>0</span><span style='background:#ffc0cb'>%</span></td><td>RESULTS: After six cycles, the <span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>85</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>0</span><span style='background:#ffc0cb'>%</span> (CR/nCR, <span style='background:#ffc0cb'>37</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>5</span><span style='background:#ffc0cb'>%</span>; very good partial<br />response [VGPR] or better, <span style='background:#ffc0cb'>57</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>5</span><span style='background:#ffc0cb'>%</span>)</td></tr>\n",
       "<tr><td>20521355.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>19</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>6</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>19</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>6</span><span style='background:#ffc0cb'>%</span></td><td>The overall <span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>19</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>6</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> confidence interval<br />[CI] <span style='background:#ffc0cb'>10</span><span style='background:#ffc0cb'>-</span><span style='background:#ffc0cb'>33</span><span style='background:#ffc0cb'>%</span>)</td></tr>\n",
       "<tr><td>20521355.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>22</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>2</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>22</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>2</span><span style='background:#ffc0cb'>%</span></td><td>Among relapse-sensitive patients, <span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>22</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>2</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI<br /><span style='background:#ffc0cb'>9</span><span style='background:#ffc0cb'>-</span><span style='background:#ffc0cb'>42</span><span style='background:#ffc0cb'>%</span>)</td></tr>\n",
       "<tr><td>20521355.txt.xmi</td><td><span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>16</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>7</span><span style='background:#ffc0cb'>%</span></td><td><span style='background:#90ee90'>ORR</span></td><td><span style='background:#ffc0cb'>16</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>7</span><span style='background:#ffc0cb'>%</span></td><td>Among relapse-refractory patients, <span style='background:#90ee90'>ORR</span> was <span style='background:#ffc0cb'>16</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>7</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI <span style='background:#ffc0cb'>5</span><span style='background:#ffc0cb'>-</span><span style='background:#ffc0cb'>37</span><span style='background:#ffc0cb'>%</span>)</td></tr>\n",
       "</table></html>"
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "%inputDir output/orr_stage1\n",
    "%outputDir output/orr_stage2\n",
    "%csvConfig ORR keyword value sentence\n",
    "%saveCSV output/orr_result_table.csv\n",
    "s:Sentence->{\n",
    "    (i:ORRInd v:Value){-> CREATE(ORR, \"keyword\"=i, \"value\"=v, \"sentence\"=s)};\n",
    "    (v:Value i:@ORRInd){-> CREATE(ORR, \"keyword\"=i, \"value\"=v, \"sentence\"=s)};\n",
    "    (i:ORRInd SW v:Value){-> CREATE(ORR, \"keyword\"=i, \"value\"=v, \"sentence\"=s)};\n",
    "    };\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "joint-framework",
   "metadata": {
    "kernel": "SoS"
   },
   "source": [
    "## Additional Error Analysis: Sentences with ORR indicator, but without match\n",
    "It is easy to spot False Positives (sentences where an ORR value has been found) in the above table. On the other hand, False Negatives are not possible to detect with the above table alone. For that reason, it is useful to highlight similar key words (e.g. \"response rate\", \"RR\", \"rate of response\". This is done in the cell below."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "north-proxy",
   "metadata": {
    "kernel": "UIMA Ruta"
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Processed 100/100 files. (took 1s)\n",
      "68 rows created.\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<html><table>\n",
       "<tr><td>21249514.txt.xmi</td><td>We evaluated<br />objective <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span> (<span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span>), progression free survival (PFS), overall survival <br />(OS), and toxicity profiles</td></tr>\n",
       "<tr><td>19533023.txt.xmi</td><td>The primary end point was objective <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span> (<span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span>)</td></tr>\n",
       "<tr><td>21697017.txt.xmi</td><td>We observed modest activity with a central<br />nervous system objective <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span> of <span style='background:#ffc0cb'>13</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>%</span>; however, median PFS was<br />disappointing</td></tr>\n",
       "<tr><td>21697017.txt.xmi</td><td>The primary endpoint was CNS objective <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span> (<span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span>)</td></tr>\n",
       "<tr><td>16360546.txt.xmi</td><td>Clinical trials have shown that anthracycline-taxane combinations are more<br />effective than anthracyclines or taxanes alone in terms of overall <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span>s<br />(<span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span>), PFS and OS in women who have not received prior anthracycline<br />chemotherapy</td></tr>\n",
       "<tr><td>21937232.txt.xmi</td><td>Analysis<br />included progression-free survival (PFS), overall survival (OS), objective<br /><span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span> (<span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span>) and toxicity</td></tr>\n",
       "<tr><td>18936475.txt.xmi</td><td>Secondary end points were<br />progression-free survival (PFS), objective <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span> (<span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span>), and safety</td></tr>\n",
       "<tr><td>21750555.txt.xmi</td><td>Secondary endpoints included overall survival<br />(OS), objective <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span> (<span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span>), adverse events, and pharmacokinetics</td></tr>\n",
       "<tr><td>20723384.txt.xmi</td><td>RESULTS: Among a total of 28 patients, the objective <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span> (<span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span>) of<br />erlotinib was <span style='background:#ffc0cb'>28</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>6</span><span style='background:#ffc0cb'>%</span></td></tr>\n",
       "<tr><td>21456002.txt.xmi</td><td>The primary objective of this phase 2 study <br />was to determine the objective <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span> (<span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span>) in patients who had received 1<br />previous systemic chemotherapy for unresectable/metastatic melanoma; secondary<br />objectives were to evaluate the clinical <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span> (C<span style='background:#ff0000'>RR</span>), progression-free<br />survival (PFS), overall survival (OS), duration of response, safety, and<br />pharmacokinetics</td></tr>\n",
       "<tr><td>21456002.txt.xmi</td><td>No patients had a complete response (CR), 8 patients had a partial<br />response (PR), and 24 patients had stable disease (SD); the <span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span> (CR + PR) was<br /><span style='background:#ffc0cb'>11</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>8</span><span style='background:#ffc0cb'>%</span>, and the C<span style='background:#ff0000'>RR</span> (CR + PR + SD) was <span style='background:#ffc0cb'>47</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>1</span><span style='background:#ffc0cb'>%</span></td></tr>\n",
       "<tr><td>19804901.txt.xmi</td><td>Response rates<br />(<span style='background:#ff0000'>RR</span>) were measured using RECIST criteria or by CA-125 levels per modified Rustin <br />criteria</td></tr>\n",
       "<tr><td>19804901.txt.xmi</td><td><span style='background:#ff0000'>RR</span> and progression-free survival (PFS) were determined and plotted<br />using Kaplan-Meier survival analysis</td></tr>\n",
       "<tr><td>19804901.txt.xmi</td><td>CONCLUSIONS: Combination of paclitaxel and bevacizumab is feasible and<br />demonstrates an acceptable toxicity profile and a high <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span></td></tr>\n",
       "<tr><td>21561763.txt.xmi</td><td>The primary<br />end-point was objective <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span> (<span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span>)</td></tr>\n",
       "<tr><td>18669461.txt.xmi</td><td>The primary end point was objective<br /><span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span> (<span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span>)</td></tr>\n",
       "<tr><td>20581887.txt.xmi</td><td>Overall <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span> (<span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span>)<br />consisting of complete response and partial response (CR+PR, PFS, OS and toxicity<br />are reported</td></tr>\n",
       "<tr><td>18034592.txt.xmi</td><td>In addition, more limited noncomparative data from a large trial<br />indicated a <span style='background:#ffc0cb'>13</span><span style='background:#ffc0cb'>%</span> overall objective <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span> (<span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span>) in platinum-refractory<br />patients with SCCHN</td></tr>\n",
       "<tr><td>20819239.txt.xmi</td><td>METHODS: Data from 114 consecutive patients who had access to targeted agent were<br />analyzed for <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span>s (<span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span>), progression free survival (PFS) and overall<br />survival (OS)</td></tr>\n",
       "<tr><td>19862815.txt.xmi</td><td>BACKGROUND: The objective of this study was to independently evaluate the<br />objective <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span> of sorafenib and sorafenib plus low-dose interferon-alfa <br />2b (IFN) as frontline therapy in patients with metastatic renal cell carcinoma<br />(mRCC)</td></tr>\n",
       "<tr><td>19862815.txt.xmi</td><td>Primary endpoints included the<br />objective <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span> (<span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span>) and safety</td></tr>\n",
       "<tr><td>19861580.txt.xmi</td><td>This study aimed to<br />evaluate the incidence of CEA flare and its impact on objective <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span><br />(<span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span>), progression-free survival (PFS) and overall survival (OS)</td></tr>\n",
       "<tr><td>19861580.txt.xmi</td><td>On multivariate<br />analysis, compared with patients with increasing CEA, patients with CEA flare had<br />a significantly better <span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span> [I versus F: <span style='background:#ffc0cb'>11</span><span style='background:#ffc0cb'>%</span> versus <span style='background:#ffc0cb'>73</span><span style='background:#ffc0cb'>%</span>; risk ratio (<span style='background:#ff0000'>RR</span>): 27.96;<br /><span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> confidence interval (CI): 9.55-81.88; P < 0.001], PFS (median 3.1 versus 8.3 <br />months; <span style='background:#ff0000'>RR</span>: 0.38; <span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI: 0.26-0.56; P < 0.001) and OS (median 10.9 versus 17.7<br />months; <span style='background:#ff0000'>RR</span>: 0.53; <span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI: 0.34-0.82; P < 0.001)</td></tr>\n",
       "<tr><td>19628292.txt.xmi</td><td>The primary objective was<br />objective <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span> (<span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span>)</td></tr>\n",
       "<tr><td>21188390.txt.xmi</td><td>Overall radiological <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span> (<span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span>), overall survival (OS), and<br />toxicity were assessed as secondary outcomes</td></tr>\n",
       "<tr><td>21532504.txt.xmi</td><td>Studies<br />have shown that endostar plus vinorelbine-cisplatin chemotherapy could improve<br />objective <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span>s (<span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span>) and overall survival (OS) of advanced non-small<br />cell lung cancer (NSCLC) patients</td></tr>\n",
       "<tr><td>22078932.txt.xmi</td><td>The primary end-point was objective <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span> (<span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span>) per<br />response evaluation criteria in solid tumors (RECIST) by central imaging</td></tr>\n",
       "<tr><td>19853960.txt.xmi</td><td>Overall <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span><br />(<span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span>), progression-free survival (PFS), and overall survival (OS) were evaluated</td></tr>\n",
       "<tr><td>19652060.txt.xmi</td><td>A one-arm, single-stage design was used to estimate the primary end <br />point of objective <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span> (<span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span>), defined by RECIST (Response Evaluation<br />Criteria in Solid Tumors)</td></tr>\n",
       "<tr><td>19687333.txt.xmi</td><td>The primary end point was objective tumor <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span> (<span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span>)</td></tr>\n",
       "<tr><td>22161771.txt.xmi</td><td>The<br /><span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span><span style='background:#90ee90'>)</span> of EGFR-TKI was <span style='background:#ffc0cb'>66</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>60</span><span style='background:#ffc0cb'>%</span>, whereas the <span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span> of<br />chemotherapy regimen was <span style='background:#ffc0cb'>30</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>62</span><span style='background:#ffc0cb'>%</span>, which was also a statistically significant favor<br />for EGFR-TKI [relative risk (<span style='background:#ff0000'>RR</span>)=5.68; <span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI=3.17-10.18; p<0.001]</td></tr>\n",
       "<tr><td>21315428.txt.xmi</td><td>Response rates (<span style='background:#ff0000'>RR</span>) were calculated, and progression-free<br />survival (PFS), and overall survival (OS) were compared using Kaplan-Meier<br />survival analysis</td></tr>\n",
       "<tr><td>19386096.txt.xmi</td><td>Primary end points were objective <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span> (<span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span>) and rate of radical (R0)<br />surgical resection</td></tr>\n",
       "<tr><td>20351334.txt.xmi</td><td>Secondary end points included<br /><span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span> (<span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span>), response duration, overall survival (OS), clinical benefit, <br />quality of life (QOL), and safety</td></tr>\n",
       "<tr><td>19997960.txt.xmi</td><td>Overall <span style='background:#ff0000'>RR</span> was <span style='background:#ffc0cb'>52</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>%</span></td></tr>\n",
       "<tr><td>19287023.txt.xmi</td><td>The primary endpoint was objective <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span> (<span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span>) per<br />modified Response Evaluation Criteria in Solid Tumors (RECIST) by independent<br />central review</td></tr>\n",
       "<tr><td>21300933.txt.xmi</td><td>The<br />primary study end point was objective <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span> (<span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span>)</td></tr>\n",
       "<tr><td>20585851.txt.xmi</td><td>The primary end point was progression free survival (PFS);<br />secondary end points were <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span><span style='background:#90ee90'>)</span>, complete (CR) and partial <br />(PR) <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span>s, clinical benefit (<span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span> + stable disease), overall survival<br />(OS), and safety</td></tr>\n",
       "<tr><td>21431341.txt.xmi</td><td>An objective <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span> (<span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span>) was 11 of 21 patients (<span style='background:#ffc0cb'>52</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>4</span><span style='background:#ffc0cb'>%</span>),<br />including a complete response in 1 (<span style='background:#ffc0cb'>4</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>8</span><span style='background:#ffc0cb'>%</span>)</td></tr>\n",
       "<tr><td>22127285.txt.xmi</td><td>, the objective <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span> (<span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span>) was <span style='background:#ffc0cb'>13</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>8</span><span style='background:#ffc0cb'>%</span>, the clinical<br />benefit rate (<span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span>+SD) was <span style='background:#ffc0cb'>72</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>4</span><span style='background:#ffc0cb'>%</span>, the 6-month progression-free survival (PFS) was <br /><span style='background:#ffc0cb'>20</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>7</span><span style='background:#ffc0cb'>%</span>, and the 12-month overall survival (OS) was <span style='background:#ffc0cb'>34</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>5</span><span style='background:#ffc0cb'>%</span></td></tr>\n",
       "<tr><td>19826424.txt.xmi</td><td>The<br />primary end point was objective <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span> (<span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span>)</td></tr>\n",
       "<tr><td>19826424.txt.xmi</td><td>CONCLUSIONS: The safety profile and time-to-event analyses, albeit relatively low<br /><span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span> of <span style='background:#ffc0cb'>2</span><span style='background:#ffc0cb'>%</span>, suggest single-agent sunitinib on a CDD schedule may be a<br />potential therapeutic agent for patients with advanced, refractory NSCLC</td></tr>\n",
       "<tr><td>14962257.txt.xmi</td><td>The<br />risk to fail the collection was significantly related to the number of previous<br />chemotherapy courses (>6) (P = 0.005, <span style='background:#ff0000'>RR</span> = 1.4), to the pretransplant status (P =<br />0.04, <span style='background:#ff0000'>RR</span> = 13.5) and to the previous fludarabine administration (P = 0.01, <span style='background:#ff0000'>RR</span> =<br />20)</td></tr>\n",
       "<tr><td>14962257.txt.xmi</td><td>The<br />diagnosis of HG-NHL and the non-response to DHAP resulted to reduce respectively <br />the OS (P = 0.007, <span style='background:#ff0000'>RR</span> = 2.8) and PFS probability (P = 0.01, <span style='background:#ff0000'>RR</span> = 4.1)</td></tr>\n",
       "<tr><td>21188632.txt.xmi</td><td>The<br />primary goal of this study was to determine the objective <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span> in<br />patients with advanced or MBC given pemetrexed as a first-line, dose-dense, every<br />2-week chemotherapy</td></tr>\n",
       "<tr><td>18981463.txt.xmi</td><td>End points included<br />progression-free survival (PFS), objective <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span> (<span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span>), overall survival <br />(OS), and safety</td></tr>\n",
       "<tr><td>20430469.txt.xmi</td><td>The primary endpoint was<br />objective <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span> (<span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span>)</td></tr>\n",
       "<tr><td>20371445.txt.xmi</td><td>RESULTS: Overall <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span> (<span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span>) and complete response (CR) were similar<br />among ESHAP and R-ESHAP (<span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span>, 33 patients [<span style='background:#ffc0cb'>62</span><span style='background:#ffc0cb'>%</span>] and 28 patients [<span style='background:#ffc0cb'>60</span><span style='background:#ffc0cb'>%</span>],<br />respectively; CR, 20 patients [<span style='background:#ffc0cb'>37</span><span style='background:#ffc0cb'>%</span>] and 18 patients [<span style='background:#ffc0cb'>36</span><span style='background:#ffc0cb'>%</span>], respectively)</td></tr>\n",
       "<tr><td>20371445.txt.xmi</td><td>Although ESHAP retains the clinical <br />efficacy previously reported in nonfrail patients, the addition of rituximab did <br />not improve <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span>, PFS, or OS</td></tr>\n",
       "<tr><td>21163071.txt.xmi</td><td>The cumulative survival rate, objective <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span> (<span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span>), disease<br />control rate (DCR), progression free survival (PFS) of the cases were calculated</td></tr>\n",
       "<tr><td>20973869.txt.xmi</td><td>The primary<br />end-point was the objective <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span> (<span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span>) and the secondary end-points<br />included clinical benefit, progression-free survival (PFS), overall survival (OS)<br />and safety</td></tr>\n",
       "<tr><td>21803002.txt.xmi</td><td>Secondary endpoints included progression-free<br />survival (PFS), overall survival (OS), objective <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span> (<span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span>), and safety</td></tr>\n",
       "<tr><td>19887304.txt.xmi</td><td>Primary endpoint was objective<br /><span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span> (<span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span>)</td></tr>\n",
       "<tr><td>19652072.txt.xmi</td><td>RECIST-defined objective<br /><span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span> (<span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span>) was the primary end point</td></tr>\n",
       "<tr><td>20466745.txt.xmi</td><td>Overall <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span> (<span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span>) was <span style='background:#ffc0cb'>43</span><span style='background:#ffc0cb'>%</span> in the total<br />cohort and <span style='background:#ffc0cb'>49</span><span style='background:#ffc0cb'>%</span> in the subgroup of 17p-deleted patients (n = 35)</td></tr>\n",
       "<tr><td>18604722.txt.xmi</td><td>Outcomes of salvage<br />chemotherapy and autologous stem cell transplantation (ASCT) for relapsed or<br />refractory disease (<span style='background:#ff0000'>RR</span>) have not been well characterised</td></tr>\n",
       "<tr><td>18604722.txt.xmi</td><td>We retrospectively<br />identified 180 consecutive <span style='background:#ff0000'>RR</span> patients (37 PMLCL and a control group of 143<br />DLBCL) that underwent salvage chemotherapy</td></tr>\n",
       "<tr><td>18604722.txt.xmi</td><td>The <span style='background:#90ee90'>overall</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>response</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>rate</span><span style='background:#90ee90'> </span><span style='background:#90ee90'>(</span><span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span><span style='background:#90ee90'>)</span> to<br />salvage chemotherapy (<span style='background:#ffc0cb'>25</span><span style='background:#ffc0cb'>%</span> vs. <span style='background:#ffc0cb'>48</span><span style='background:#ffc0cb'>%</span>, p = 0.01) and 2-year OS after diagnosis of <span style='background:#ff0000'>RR</span> <br />disease (<span style='background:#ffc0cb'>15</span><span style='background:#ffc0cb'>%</span> vs. <span style='background:#ffc0cb'>34</span><span style='background:#ffc0cb'>%</span>, p = 0.018) was inferior in PMLCL patients</td></tr>\n",
       "<tr><td>18604722.txt.xmi</td><td><span style='background:#ff0000'>RR</span> PMLCL had an inferior <span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span> and survival compared with DLBCL but<br />chemosensitive PMLCL and DLBCL patients have similar outcomes post-ASCT</td></tr>\n",
       "<tr><td>16078261.txt.xmi</td><td>The primary end point<br />was the <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span></td></tr>\n",
       "<tr><td>19273714.txt.xmi</td><td>Overall <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span> (<span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span>) was <span style='background:#ffc0cb'>32</span><span style='background:#ffc0cb'>%</span> in both arms, and<br />overall survival (OS) was not different between arms (P =</td></tr>\n",
       "<tr><td>20682548.txt.xmi</td><td>Secondary end points were<br />progression-free survival (PFS), objective <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span>s (<span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span>) and toxicity</td></tr>\n",
       "<tr><td>20682548.txt.xmi</td><td>However, a high <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span> of ~<span style='background:#ffc0cb'>40</span><span style='background:#ffc0cb'>%</span> makes GP a promising second-line<br />treatment option for patients with metastatic UC</td></tr>\n",
       "<tr><td>20367963.txt.xmi</td><td>Objective <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span> (<span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span>) was achieved in <span style='background:#ffc0cb'>18</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>8</span><span style='background:#ffc0cb'>%</span> and clinical benefit<br />(CR + PR + SD > 6 months) in <span style='background:#ffc0cb'>68</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>8</span><span style='background:#ffc0cb'>%</span></td></tr>\n",
       "<tr><td>21498742.txt.xmi</td><td>RESULTS: Overall, the objective <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span> (<span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span>) was <span style='background:#ffc0cb'>29</span><span style='background:#ffc0cb'>.</span><span style='background:#ffc0cb'>3</span><span style='background:#ffc0cb'>%</span> (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span> CI: 20-40)</td></tr>\n",
       "<tr><td>21128114.txt.xmi</td><td>Analysis included overall survival (OS),<br />progression-free survival (PFS), objective <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span> (<span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span>), and safety</td></tr>\n",
       "<tr><td>20580219.txt.xmi</td><td>The overall pooled relative ratio (<span style='background:#ff0000'>RR</span>) for <span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span> was 0.24 (<span style='background:#ffc0cb'>95</span><span style='background:#ffc0cb'>%</span><br />confidence intervals (CI): 0.16-0.38; P<0.01) when mutant KRAS patients were<br />compared with wild-type KRAS patients</td></tr>\n",
       "<tr><td>20521355.txt.xmi</td><td>METHODS: This trial aimed to achieve a <span style='background:#ffc0cb'>20</span><span style='background:#ffc0cb'>%</span> objective <span style='background:#ff0000'>response</span><span style='background:#ff0000'> </span><span style='background:#ff0000'>rate</span> (<span style='background:#90ee90'>O</span><span style='background:#90ee90'>RR</span>) in<br />platinum-sensitive patients</td></tr>\n",
       "</table></html>"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "%inputDir output/orr_stage2\n",
    "%outputDir output/orr_stage3\n",
    "%csvConfig SentenceWithIndButNoORR\n",
    "\n",
    "DECLARE Ind;\n",
    "DECLARE SentenceWithIndButNoORR;\n",
    "\n",
    "\"RR\" -> Ind;\n",
    "\"response rate\" -> Ind;\n",
    "\"rate of response\" -> Ind;\n",
    "i:Ind{PARTOF(ORRInd) -> UNMARK(i)};\n",
    "Sentence{CONTAINS(Ind),-CONTAINS(ORR)->SentenceWithIndButNoORR};\n",
    "\n",
    "COLOR(Ind, \"red\");"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "UIMA Ruta",
   "language": "ruta",
   "name": "ruta"
  },
  "language_info": {
   "codemirror_mode": "ruta",
   "file_extension": ".ruta",
   "mimetype": "text/ruta",
   "name": "UIMA Ruta",
   "pygments_lexer": "ruta",
   "version": "3.0.1"
  },
  "sos": {
   "kernels": [
    [
     "SoS",
     "sos",
     "",
     "",
     "sos"
    ],
    [
     "UIMA Ruta",
     "ruta",
     "ruta",
     "",
     "ruta"
    ]
   ],
   "panel": {
    "displayed": false,
    "height": 0
   },
   "version": "0.22.4"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
